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Multiple sclerosis (MS) is a neurodegenerative disease that affects over 2 million people 
worldwide. MS results in disabling and troublesome symptoms due to damage to the brain and 
spinal cord. Pharmaceutical options exist for the management of MS and its associated 
symptoms. Some individuals with MS utilize Cannabis to help manage their symptoms. 
Cannabinoid use in MS animal models have shown promise, and evidence supporting the 
indication(s) for Cannabis in MS is rapidly evolving and highly relevant to clinical practice. 
Currently one formulation of Cannabis (Sativex®) has Health Canada approval as an adjunct 
treatment option for MS-related spasticity and pain.  
A systematic review was conducted to examine the literature on Cannabis-based 
medicine (CBM) use in MS. Medline, Embase, and International Pharmaceutical Abstracts were 
searched for articles related to MS and CBM in February 2018. All human studies, with 
outcomes specific to MS, and published in English, were eligible for inclusion. There was no 
publication year limit and no restrictions based on study design. Articles were screened 
independently by two reviewers, first by title and then by abstract. Two reviewers then 
independently performed data extraction on all included articles, and a quality assessment using 
a modified Downs and Black assessment tool. Included articles were categorized by their 
primary outcome into the following categories: spasticity, tremor, pain, cognition, 
balance/walking, bladder dysfunction, general symptoms, adverse events/safety, or disease 
progression. Reporting followed the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guidelines. 
After removal of duplicates, 2058 articles were identified, with 60 studies meeting the 
inclusion criteria. Twenty-six articles were randomized controlled studies and 34 utilized a non-
randomized study design. Cannabidiol and delta-9-tetrahydrocannabidiol oromucosal spray 
(Sativex®) was the most commonly studied CBM for MS. The dose size and frequency of 
administration between studies was inconsistent. Spasticity was the most common MS symptom 
to be treated with CBM (n=29), followed by pain (n=8) and cognition (n=6). Twenty-three 
studies were poor quality, 14 were fair quality, and 23 were good/excellent quality. CBM 
showed a trend of reducing spasticity and pain in individuals with MS; however, the variable 
quality of the evidence requires consideration when examining results of individual studies. 




This systematic review outlines the potential of CBM to treat MS spasticity and pain, 
however more research is needed to examine its use for other MS symptoms. Additionally, the 
use of other cannabinoid products for MS treatment, the effects of administering CBM with 
current MS medications, and possible long-term impacts of CBM in those with MS need to be 
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Multiple sclerosis (MS) is a neurodegenerative disease, and the most common cause of non-
traumatic disability in young adults.1 Although the underlying cause of MS is unclear, a 
combination of factors, including environmental exposure(s) and genetics, likely contribute to 
the development and progression of this disease.2 Symptoms of MS are highly unpredictable, and 
often worsen as the disease progresses,3 causing a decreased quality of life.4–6 Currently, many 
symptomatic and disease-modifying therapies exist; however, many people with MS find these 
to be unsuccessful, and improved treatment options are still needed. Cannabis may have a 
potential role in mitigating MS symptoms. Cannabis-based medicines (CBMs) are available for 
MS, but more robust evidence is needed to determine the therapeutic value of CBMs. This 
systematic review aims to examine and critically appraise the current literature on CBM for the 





CHAPTER 1: LITERATURE REVIEW 
 
1.1 Multiple Sclerosis Disease Burden 
 
Multiple sclerosis (MS) is a neurodegenerative disorder that generally presents early in 
adulthood. Most MS patients are typically diagnosed between ages 20 and 40 and MS is one of 
the main causes of non-traumatic disability in young adults.1 The incidence of MS is higher in 
women, with 3 times more women having the disease than men.7,8 In 2016, the global prevalence 
of MS was over 2 million, a 10.4% increase since 1990.9 Regions with the highest MS 
prevalence include North America, Western Europe, and Australia.9 In Canada, 77,000 adults 
(20 years and older) were living with MS in 2014/2015, equating to 1 per 358 Canadians.7 While 
the incidence of MS in Canada remains relatively constant, prevalence is increasing,10 likely due 
to increased survival times of those with MS.8,10 The number of individuals in Canada living 
with MS is projected to increase to 133,635 cases by 2031.11 This represents an important 
increase in disease burden within the Canadian population. 
 
1.2 Multiple Sclerosis  
 
Multiple sclerosis is a neurodegenerative autoimmune disease of the central nervous 
system (CNS) that causes degradation of myelin and CNS inflammation, as well as axonal 
degradation.12 Myelin, the “white matter” of the brain and spinal cord, is a fatty layer that wraps 
around neurons to allow for fast, efficient nerve impulse transmission.13 In MS, myelin is 
degraded resulting in an interruption in neuronal transmission and lesions in the brain and spinal 
cord.13–15 These lesions account for the symptoms of MS.14 A continued degradation and lack of 
myelin re-synthesis results in progression of the disease and worsening of symptoms.3,16 Axonal 
loss also occurs in MS, either before or after immune destruction of myelin, and contributes to 
the symptoms and progression of the disease.12  
 
1.2.1 Causes of Multiple Sclerosis 
 
The underlying cause of MS is unknown.17,18 It is generally accepted that MS is caused 




developing MS is 1/330; this increases to 1/67 for children of those with MS, 1/37 for siblings of 
those with MS, and 1/5 for those with an identical twin with MS.20 Additionally, age of MS onset 
is similar for monozygotic twins suggesting a genetic basis.2 Regions farther from the equator, 
including Canada,21 have a higher prevalence of MS.2 This suggests environmental factors, such 
as lack of ultraviolet radiation (UVR) and Vitamin D, influence the development and progression 
of the disease.19,22,23 Regardless of underlying cause, MS develops following an immune 
response that leads to neuronal cell death, demyelination, and neuronal dysfunction.18,24 The 
possible immune pathways that cause MS are incompletely understood,17 but immune B-cell 
activation of T-cells25–27 and subsequent myelin degradation results in tissue damage and CNS 
lesions. This causes MS symptoms.24  
 
1.2.2 Disease Course 
 
Four main disease courses characterise MS: clinically isolated syndrome (CIS), 
relapsing-remitting MS (RRMS), secondary-progressive MS (SPMS), and primary-progressive 
MS (PPMS).28 Clinically isolated syndrome (CIS) is defined as having a single “episode” of MS-
like symptoms. When examined further (i.e. by MRI), evidence of abnormalities in the brain 
and/or spinal cord are usually found.28 People who experience CIS may or may not develop MS 
in the future.29 Relapsing-remitting MS (RRMS) is the most common type of MS, affecting 
approximately 85% of individuals.30–32 With RRMS, the individual experiences relapses where 
symptoms present or worsen, followed by periods of remission or improvement.3,28 These 
relapses are due to activation of immune cells in the CNS and inflammatory damage to neuronal 
myelin sheaths.33 Approximately 80% of those with RRMS eventually develop SPMS.30 SPMS 
is characterised by a steady progression of the disease with a decrease in distinct relapses, and is 
generally less inflammatory in nature than RRMS28,34 Primary-progressive MS occurs in 10-15% 
of MS patients,19 and is characterised by a continuous progression of the disease and disability 
from onset, with no relapses, and no periods of remission.28 Finally, while not yet considered 
part of the main disease course of MS, radiologically isolated syndrome (RIS) occurs when MRI 





1.2.3 Diagnosis of Multiple Sclerosis 
 
No solitary clinical feature or test can diagnose MS. 31 A diagnosis is often made after a 
thorough clinical history of past and current symptoms and typically requires an MRI.32 The  
McDonald criteria, first established in 2001 and revised in 2005, 2011, and 2017,35,36 is the 
current criteria for diagnosing MS. According to these criteria, the diagnosis of MS requires 
dissemination is space with at least two distinct lesions anatomically located in the central 
nervous system over time.19,35–37 Dissemination in space and time may be satisfied by clinical 
and/or MRI criteria.19,35,36 Presence of cerebrospinal fluid (CSF)-specific oligoclonal bands may 
also demonstrate dissemination in time.36 Evoked potential studies may find lesions that are 
clinically silent, but these are not commonly used in diagnostic work-ups.19   
 
1.2.4 Multiple Sclerosis Symptoms and Assessment Measures 
 
The symptoms of MS are highly variable and unpredictable and depend on the affected 
region of the CNS.38 Symptoms include balance problems and dizziness, bladder and bowel 
dysfunction, cognitive impairment (especially processing speed and short-term memory), 
depression, fatigue, difficulty with mobility or gait, optic neuritis, pain, numbness/tingling, 
sexual dysfunction, spasticity, tremor, heat intolerance (Uhthoff’s Phenomenon), weakness, and 
impaired coordination.38,39 Among the most common symptoms are fatigue, pain, and cognitive 
changes, affecting 90%, 50%, and 40-70% of those with MS, respectively.38 
Different assessment measures are available to quantify the severity of MS symptoms and 
to assess the impact of symptoms on a person’s function. These assessment measures have 
variable use with some being more widely used/recognised than others. The assessment 
measures are either self-reported or assessor-reported tools (Table 1.1). A Multiple Sclerosis 
Task Force, associated with the Academy of Neurologic Physical Therapy, reviewed 63 
measures of MS symptoms and 10 were deemed “highly recommended” (marked in Table 1.1) 





Table 1.1.Assessment measures for multiple sclerosis symptoms  
Name of 
outcome  










Assesses muscle tone as follows: 0, normal tone; 1, slight increase in muscle tone, 
“catch” and release, or minimal resistance at the end of the range of motion when 
limb is moved in flexion or extension; 2, more muscle tone through range of 
motion, but limbs still easily moved; 3, substantial increase in muscle tone; 4, 
rigid limb in extension or flexion.42 The MAS also has 1+ between scores 1 and 2, 
to indicate a slight increase in muscle tone, “catch”, and minimal resistance 
throughout the remainder (less than half) of the range of motion.42 
No 
NRS Subjects report their level of spasticity from 0 (no spasticity) to 10 (worst possible 
spasticity).43 
Yes 
H/M ratio The ratio between the maximum H reflex and maximum M response to measure 
the level of spasticity.44 The H reflex is usually increased with spasticity while the 
M response, the maximum response of a muscle when the motor nerve is directly 
stimulated, is not.44 The H/M ratio is calculated using nerve conduction study 
techniques.44 For the H reflex, the sensory fibers are stimulated directly, they 
travel to the spinal cord where they synapse and then stimulate the motor nerve 
creating a delayed sub-maximal motor response.44 
No 
TTF This measure is defined as termination of treatment (withdrawal) before Visit 3, 
or worsening spasticity (increase in NRS score), or increase in, or addition of, 




A neurophysiological measure that is exaggerated in MS and can be recorded via 
electromyography (EMG) to quantitatively assess spasticity in major joints (wrist, 
knee, elbow and ankle). During the procedure, the evaluator repeatedly moves the 
distal segment of the joint over the range of motion in order to obtain EMG 










Physician rates deep tendon reflexes, resistance to leg stretches, and abnormal 
reflexes on a scale of 0 (absent) to 4 (abnormally increased) and calculates the 





Assesses efficacy of treatment spasticity as follows: greatly improved, slightly 





A dichotomous (yes/no) answer was given for ‘response’ based on the prescribing 




OABSS Seven-item questionnaire assessing overactive bladder symptoms (i.e. daytime 
frequency, nighttime frequency, urgency, incontinence).52,53 The score range is 





Subjects record voided (plus catheterised where applicable) urine volumes in a 










Table 1.1.Assessment measures for multiple sclerosis symptoms  
Name of 
outcome  
Description of outcome Patient-
reported 
outcome  
PASAT Assesses auditory information and processing speed, as well as calculation 
ability58 in which the subject is presented with a number every 3 seconds, and the 
subject must add the new digit to the one before it.59 Part of the MSFC.59 
No 
10/36 SRT Measure of visuospatial memory60 in which 10 pieces are placed on a checker-
board. For three trials, participants look at the board for 10 seconds. The 
participant then needs to replicate the pattern on another board. After 20-25 






Postural tremor (scored in outstretched and batwing positions) and intention 
tremor severity were scored individually (0-10) in each arm and then added to get 
the total score (0-60).62,63 
No 
9-HPTa A motor task in which the subject picks up nine pegs one at a time and as quickly 
as possible puts them in nine holes. Once they are in the holes, the subject 
removes them again as quickly as possible, one at a time. The time to complete 
the task is the score. Two trials with the dominant hand are followed by two trials 
with the non-dominant hand.64 Part of the MSFC.59 
No 
Disability Progression 
EDSS 10-point scale, with 0.5 point increments, to quantify MS disability.65 A score of 
1 to 4.5 indicate someone with MS who is able to walk without any aid. A score 
of 5 to 9.5 indicate an impairment in walking.65 
No 
MSFCa 1) Timed 25-Foot walk; 2) 9-Hole Peg Test (9-HPT); and 3) Paced Auditory 





25-item questionnaire measuring a person’s perception of disability and handicap 
(either “always” (4 points), “sometimes” (2 points) or “never” (0 points)) in three 
areas: physical, emotional, functional. The higher the total score (out of a possible 
100), the worse the handicap.59,66 
Yes 
Pain 
NRS Self-reported pain scale in which the subject rates their pain from 0 (no pain) to 
10 (worst pain imaginable).67  
Yes 
VAS This scale uses a 100 mm straight line with “no pain at all” (0 mm) on one side 
and “pain as bad as it could be” (100 mm) on the other.68,69 The subject then 
marks their pain on the line, indicating their level of pain.68,69 
Yes 
CRS The CRS is an 11-point rating scale (0 to 10) to evaluate the subjects’ perceived 
change in muscle stiffness, with 0 being very much better and 10 being very 





The subject, starting in a standing and upright position, is instructed to walk 25 
feet in a straight line as fast and safely as possible. The subject is able to use an 
assistive device. The time to perform the walk twice is measured and the average 





This scale consists of 14 functional balance tasks of increasing difficulty 
performed by the participant and rated by the assessor. A four-point scoring scale 




The AI is a rating scale that assesses mobility based on time and degree of 





Table 1.1.Assessment measures for multiple sclerosis symptoms  
Name of 
outcome  
Description of outcome Patient-
reported 
outcome  
is scored on a 10-point scale with anchors of asymptomatic and fully active (0) 
through bedridden (10).71 
Postural 
Sway 
Measure of dynamic posturography in which a subject stands on a force plate and 
is led through a series of conditions (eyes open, eyes closed, etc.) in order to 






A 12-item scale where subjects rank each item from 1 (not at all) to 5 (extremely). 




Patients were instructed to walk at a quick yet comfortable pace back and forth 
along a pre-measured walkway for 6 minutes. At the end of 6 minutes, the total 





Measure of dynamic balance. The subject stands from a chair and walks 3 m, then 
walks back to the chair and sits down. The time is from when the pelvis lifts off 
the chair to when it reaches the chair again. For cognitive portion, the subject has 




Measure of walking ability in which subjects walk barefoot at a self-selected 
speed on a 10 m walkway at least six times, and the speed is recoreded77 
No 
Quality of Life 
MSQOL-
54a 
Self-reported 54-item scale assessing subjects’ overall perception of quality of 
life. There are 2 subscales along with two summary scores, and two additional 
single-item measures, all with their own rating measures. This scale touches on 
physical function, pain, emotional well-being, energy, social functions, cognitive 
function, overall quality of life, and sexual function.78 
Yes 
MSIS-29a This self-reported assessment measures the psychological and physical effect of 
MS.79 It is a 29-item questionnaire where subjects assess items relating to 
physical and mental health and wellbeing over the past two weeks. Items are 
ranked from 1 (not at all) to 5 (extremely).80 
Yes 







The Visual Analogue Scale (VAS) score for the subject’s chosen symptom.82  Yes 
9-HPT: 9-hole peg test; 10/36 SRT: 10/36 spatial recall test; AI: ambulation index; CRS: category rating scale; DSM: 
diagnostic and statistical manual of mental disorders; EDSS: expanded disability status scale; MSFC: multiple sclerosis 
functional composite; MSIS: multiple sclerosis impact scale; MSQOL: multiple sclerosis quality of life; NRS: numerical 
rating scale; OABSS: overactive bladder symptom score; PASAT: paced auditory serial addition test; PDQ: perceived 
deficits questionnaire; SDMT: symbol digit modality test; SCID-IV: structured clinical interview for diagnostics and 
statistical manual of mental disorders (DSM-IV) axis I disorders; TTF: time to treatment failure; TUG: timed up-and-go; 
VAS: visual analogue scale;  







1.2.5 Treatment for Multiple Sclerosis  
 
As there is no cure for MS, current therapies aim to treat acute relapses, decrease or slow 
disease progression, or treat symptoms associated with MS.14,39,83 Treatment of acute relapses 
may involved the use of high dose corticosteroids (IV methylprednisolone or high dose oral 
prednisone), and adrenocorticotropin hormone (ACTH).84,85 These therapies have anti-
inflammatory and immunosuppressive properties86 and target active immune cells and 
inflammation present during a relapse.33 For disease progression, disease-modifying therapies 
(DMTs) are available,87 which reduce relapses and the number of new lesions seen on imaging in 
clinical trials.88–90 Debate exists, though, as to their effectiveness on disability outcomes long-
term.91 DMTs are effective for relapsing forms of MS, as they target active inflammatory 
disease,87,92,93 however they are less efficacious once degeneration begins.1 Over a dozen 
treatments are available for relapsing remitting MS,94 but only one disease modifying therapy, 
ocrelizumab, is currently approved for PPMS.95 The reduced effectiveness of DMT’s in PPMS 
may be explained by fewer active plaques and inflammation in progressive MS.34 In Canada, 
first-line treatments for MS include the beta-interferons, glatiramer acetate, teriflunomide, 
dimethyl fumarate, and ocrelizumab,88,92,95,96 while second-line treatment options include 
fingolimod, natalizumab, alemtuzumab, and cladribine.88,92,96 For symptomatic treatment, a large 
number of drug therapies are available (Table 1.2), particularly for bladder, spasticity, and 
pain,14,39,97 however these options are not without side effects.14,98–101 There are also limited 
options for MS fatigue and cognitive dysfunction,14,39,97,101 and off-label use of drugs for both 
disease progression102 and symptom management is not uncommon.14,39,97,101 This highlights the 










Table 1.2. Symptomatic therapy used for various symptoms of multiple sclerosis in Canada.14,39,97 
Symptom Treatment Options 
Spasticity • muscle relaxant: baclofen  
• alpha-2 adrenergic agonists: tizanidine  
• benzodiazepines: diazepam, lorazepam   
Pendular Nystagmus  • NMDA receptor antagonist: memantine 
• anti-convulsant: gabapentin 
• corticosteroid: methylprednisone (IV), prednisone (oral) 
Pain • anti-convulsant: gabapentin, pregabalin, carbamazepine, phenytoin 
• TCAs: amitriptyline, nortriptyline  
• benzodiazepines: lorazepam  
• muscle relaxant: cyclobenzaprine, baclofen, methocarbamol 
• narcotic analgesic: acetaminophen-oxycodone  
Heat Sensitivity  • potassium channel blocker: fampridine SR 
Bladder /LUTS • botulinum A toxin 
• anticholinergics: oxybutynin, darifenacin, solifenacin succinate, 
flavoxate  
• anti-diuretic: desmopressin  
• alpha-1 blockers: prazosin, tamsulosin, darifenacin  
• beta-3 adrenergic agonists: mirabegron 
• TCAs: imipramine  
Gait • potassium channel blocker: fampridine SR  
Fatigue • CNS stimulant: methylphenidate, amantadine, modafinil 
Tremor • anticonvulsants: gabapentin, levetiracetam, topiramate, primidone  
• beta-blockers: propranolol  
• antibiotic: isoniazid  
Sexual dysfunction • erectile dysfunction: sildenafil nitrate, alprostadil, papaverine, tadalafil, 
vardenafil 
• anti-convulsant: carbamazepine, phenytoin  
Bowel Dysfunction  • stool softener: docusate oral 
• laxative: bisacodyl, sodium phosphate, psyllium hydrophilic mucilloid, 
magnesium hydroxide  
Cognitive Dysfunction • amphetamines 
• acetylcholinesterase inhibitors: donepezil  
Depression • SSRIs: sertraline, citalopram, fluoxetine, paroxetine 
• TCAs: amitriptyline, nortriptyline 
• SNRIs: mirtazapine, venlafaxine, desvenlafaxine 
CNS: central nervous system; LUTS: lower urinary tract symptoms; NMDA: N-Methyl-D-aspartic acid; SSRI: selective 
serotonin reuptake inhibitor; SNRI: serotonin-norepinephrine reuptake inhibitor TCA: tricyclic antidepressant 
 
1.2.5.1 Complementary and Alternative Medicine  
 
Individuals living with MS often try complementary and alternative medicine (CAM) 
acupuncture, aromatherapy, Ayurveda, chiropractor, electromagnetic therapy, homeopathy, 
hypnosis, massage, naturopathy, and Reiki.103 Furthermore, some turn to self-medication with 




Multiple Sclerosis (NARCOMS) registry evaluated Cannabis use in MS and found that 47% of 
5481 survey respondents considered Cannabis a possible option to treat the symptoms of MS.106 
Currently, a limited evidence-base exists for Cannabis and Cannabis-based medicine (CBM) use 
in MS. Therefore, future studies evaluating Cannabis and CBM should focus on which MS 
symptoms are best treated with CBM, which cannabinoid(s) is most beneficial for specific MS 
symptoms, the best route of administration (oral, oromucosal, inhalation), the negative effects of 
CBM and if they subside with prolonged use, and possible interactions between CBM and other 
MS medications.107  
 
1.3 Endocannabinoid System 
 
The endocannabinoid system works throughout the body and is very prevalent in the 
CNS, as a synaptic regulator,108 and in immune microglial cells.109 The endocannabinoid system 
has three elements: various receptors; the endogenous cannabinoids that act on these receptors; 
and the enzymes that synthesise and breakdown endocannabinoids.110 The synthesis and 
subsequent activity of endocannabinoids with cannabinoid receptors modulate neurotransmitter 
release.  
 
1.3.1 Receptors of the Endocannabinoid System 
 
The cannabinoid receptors are rhodopsin-like G-protein coupled receptors (GPCRs),111,112 
which are located throughout the body (Figure 1.1).113 Both exogenous and endogenous 
cannabinoids interact with these receptors causing an inhibition in neurotransmitter release.114,115 
Cannabinoids also interact with other receptors, including transient receptor potential vanilloid 
type-1 (TRPV1) and the GPCR, GPR55.116 The actions of cannabinoids result in various 
pharmacological effects, some of which may be beneficial for the treatment of many different 
conditions.  
CB1 receptors are the most abundant GPCR in the CNS with high expression in both the 
brain and spinal cord.117 In the brain, CB1 is highly expressed in the hippocampus, cortex, 
cerebellum, and basal ganglia, brain areas associated with memory and motor control.118,119 CB1 




a useful option for pain therapies. CB1 receptors present on microglial cells are involved in 
immune mediation.121 
CB2 receptors are peripherally located on immune cells, including B- and T-cells and 
monocytes, as well as in immune tissues, such as the spleen and tonsils.122 This receptor is also 
expressed in the brain and spinal cord, but to a limited degree.118,123 CB2 receptors may be a 
target for various immune responses and, therefore, can be useful in neuropathies that involve 
excessive inflammation.124 CB2 receptor upregulation may occur in the CNS during 
inflammation with expression mainly in microglia, the macrophages of the CNS.124 Therefore, 
CB2 receptor activation can lead to protection against neuroinflammation.  
Cannabinoids can interact with other receptors in addition to CB1 and CB2 receptors. 
These include the transient receptor potential vanilloid type-1 (TRPV1) and the GPCR, 
GPR55.116 Both are located in the CNS, 125–128 with TRPV1 also involved in pain 
management.128 Endocannabinoids do not activate GPCR GPR18, which is also abundant in the 
CNS and microglial cells;129–131 however, exogenous cannabinoids interact with this receptor.116  
 
1.3.2 Endogenous Cannabinoids 
 
Anandamide (AEA) and 2-arachidonylglycerol (2-AG) are the two principal 
endocannabinoids that act on cannabinoid receptors. The synthesis of AEA and 2-AG, from 
precursors located in the cell membrane,132 is mediated by N-acetylphosphatidylethanolamine-
hydrolyzing phospholipase D (NAPE-PLD) and diacylglycerol lipase (DAGL), 
respectively.114,115 Through the interaction with cannabinoid receptors, endocannabinoids are 
able to inhibit neurotransmitter release and neuronal signalling.114 AEA is a partial agonist of the 
CB1 receptor, while 2-AG is a full agonist of both the CB1 and CB2 receptors.114,133,134 After 
interaction with cannabinoid receptors, AEA is degraded by fatty acid amide hydrolase (FAAH) 
into arachidonic acid (AA) and ethanolamine, while 2-AG is degraded by monoacylglycerol 






Figure 1.1. Location of CB1 and CB2 receptors in the body. Locations of CB1 
receptors are in green, location of CB2 receptors are in yellow, and locations with 
both CB1 and CB2 receptors are in blue. 
Location of CB1 and CB2 receptors around the body from © Fundación CANNA. 
(n.d.). The Endocannabinoid System. Fundación CANNA. Retrieved from 




1.3.3 Mechanism of Action of Endocannabinoids 
 
The endocannabinoids, AEA and 2-AG,111 are retrograde synaptic messengers with a 
complex mechanism of action. AEA and 2-AG interaction with pre-synaptic CB1 receptors 
results in inhibition of pre-synaptic activity.119 The CB1 receptor suppresses neurotransmitter 
release in two ways: inhibition of voltage-gated Ca2+ channels on the presynaptic cell and 
induction of long-term depression (LTD).114,115 With post-synaptic depolarization, voltage-gated 
Ca2+ channels open increasing intracellular calcium,132,135 which subsequently activates N-
acetyltransferase (NAT) and phospholipase C (PLC).132,135 The activation of NAT converts 
phosphatidylethanolamine (PE) to N-arachidonoyl phosphatidylethanolamine (NAPE).132,135 
NAPE is metabolized to AEA through the activity of NAPE-PLD.132,135 Similarly, the activation 




converted to 2-AG by DAG lipase (DAGL) .135 mGluR1/5 activation in the post-synaptic neuron 
can also cause activation of PLC, resulting in synthesis of DAG. DAG is then cleaved by DAGL 
resulting in 2-AG synthesis.119,136 The newly synthesised endocannabinoids then leave the post-
synaptic cell and move in a retrograde manner to activate CB1 receptors on the pre-synaptic 
cell.119,136 The binding of cannabinoids to CB1 on the pre-synaptic cell leads to G-protein 
activation, and the subsequent dissociation of the Gβγ and Gαi subunits. The Gβγ subunit causes 
inwardly-rectifying K+ channels to open,135,137 allowing K+ to enter the presynaptic cell. It also 
causes Ca2+ channels to close, inhibiting the influx of Ca2+ into the pre-synaptic cell.119,136 The 
influx of K+ and inhibition of influx of Ca2+ results in hyperpolarization of the pre-synaptic cell. 
This hyperpolarization prevents release of neurotransmitters.119,136 Gαi subunit activation inhibits 
the adenylyl cyclase-phosphokinase A (AC-PKA) pathway, therefore decreasing the formation 
of cyclic AMP (cAMP), resulting in LTD.108,137  
 
Once synthesized, AEA and 2-AG may enter the post- or pre-synaptic neuron, 
respectively, and undergo inactivation by enzymatic hydrolysis.110,135 The two major 
endocannabinoid-metabolizing enzymes are fatty acid amide hydrolase (FAAH) and 
monoacylglycerol lipase (MAGL), which catabolize AEA and 2-AG, respectively.132 The amide 
bond of anandamide is hydrolyzed in the post-synaptic cell by FAAH to yield arachidonic acid 
(AA) and ethanolamine (ETA).110,132 The ester bond of 2-AG is hydrolyzed in the pre-synaptic 
cell by MAGL to yield arachidonic acid (AA) and glycerol.110,132 The products of the catalysis 
are then recycled into phospholipids that can integrate into the cell membrane.132 
Since the discovery of endocannabinoids and their mechanism of action, it has been 
thought that this system can be exploited by synthetic and exogenous cannabinoids for 
therapeutic uses. Cannabinoid use for the treatment of neurological disorders is increasing and 
show promise for epilepsy, neuropathic pain, and MS.138–140 Additionally, their presence on 
immune cells suggest their involvement in inflammation and immune mediation and, hence, 









Figure 1.2. Mechanism of action of cannabinoids at the CB1 receptor, causing inhibition of calcium (Ca2+) channels and activation of 




1.4 Cannabinoids and MS 
 
Cannabinoid receptor presence in the CNS allows cannabinoids to inhibit 
neurotransmitter release, ameliorating MS symptoms. Nerve impulse transmission results in the 
release of the presynaptic excitatory neurotransmitter, glutamate,142 which subsequently crosses 
the synapse and binds to ionotropic glutamate receptors in the synaptic cleft.142 Glutamate 
receptor binding leads to an ionic flux of calcium that induces the potentiation of a nerve impulse 
down the neuron.142 In normal conditions (Figure 1.3A), both movement and sensation are 
controlled by the nervous system balancing excitatory and inhibitory signals. In disease states 
such as MS (Figure 1.3B), the damage to the nervous system, due to the loss of myelin, causes an 
increase in glutamate release, which leads to an excess of excitation and neurotransmitter 
signalling.142,143 This results in the symptoms associated with MS.142,143 Invading immune cells 
and glial cells can increase this glutamate release, leading to more excitation.142,144,145 Moreover, 
GABAergic inhibitory nerves are lost in MS, leading to a loss of ability to counteract the 
excessive excitation.142,143 Excessive glutamate excitotoxicity can lead to metabolic failure and 
subsequent accumulation of calcium with further nerve loss and greater disability.142,146,147 
Cannabinoids acting on the CB1 receptor can limit excitotoxicity and slow nerve loss, therefore 








Figure 1.3. Neurotransmission of neuronal impulses in normal conditions (A), MS disease 
state (B), and MS disease state with the use of cannabinoids acting on CB1 receptors (C). 
Neurotransmission under normal conditions (A), during MS disease progression (B), and 
subsequent cannabinoid control of neurotransmission in disease states (C) from © Baker, D., 
Pryce, G., Jackson, S. J., Bolton, C., & Giovannoni, G. (2012). The biology that underpins the 
therapeutic potential of cannabis-based medicines for the control of spasticity in multiple 





In immune-mediated demyelinating conditions, such as MS, activation of CB2 receptors 
can, in theory, decrease the harmful inflammatory response that causes the death of both young 
oligodendrocyte precursor cells as well as mature oligodendrocytes to enhance cell survival.149 
Moreover, CB2 receptor agonism may not only stop demyelination, but may promote the repair 
of damaged axons.149 Therefore, CB2 receptors could be involved in both the protection and 













Much anecdotal evidence is present to suggest that CBM can alleviate symptoms 
associated with MS. This evidence, in combination with the known cannabinoid receptor 
presence throughout the body and involvement in immune mediation, underlines the basis that 
CBM may improve some MS symptoms, and potentially slow disease progression.  
 
Figure 1.4. CB2 receptor agonism as a mechanism of neuroprotection 
and remyelination in MS. 
CB2 receptor agonism as a mechanism of neuroprotection and 
remyelination from © Arévalo-Martín, A., García-Ovejero, D., Gómez, 
O., Rubio-Araiz, A., Navarro-Galve, B., Guaza, C., … Molina-Holgado, 
F. (2008). CB2 cannabinoid receptors as an emerging target for 
demyelinating diseases: from neuroimmune interactions to cell 
replacement strategies. British Journal of Pharmacology, 153(2), 216–25. 






 Phytocannabinoids are found in the Cannabis plant, Cannabis sativa, and interact with 
the endocannabinoid system. This plant contains over 140 different cannabinoids, with the most 
prominent ones being Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD),150,151 as well as 




THC, the main psychoactive component of Cannabis, is responsible for the signature 
“high” of marijuana, with side effects including sedation and intoxication.154 THC is a partial 
agonist of both CB1 and CB2 receptors,155 and its action at the CB1 receptor is responsible for its 
regulation of synaptic transmission142,143 and psychoactive effects.137 THC also has 
immunosuppressive properties.154 The actions of THC at the CB1 receptor, and with the immune 




CBD, the other main cannabinoid present in cannabis, is non-intoxicating. CBD does not 
bind to either CB receptor, but it is a negative allosteric modulator (NAM) of the CB1 
receptor.155 It may act as a neuromodulator,156 as well as have anti-inflammatory and 
immunosuppressive properties such as inhibiting pro-inflammatory cytokines and activating anti-
inflammatory pathways in microglial cells.157 Therefore, CBD is thought to be especially useful 
candidate in ameliorating the progression of autoimmune disorders, including MS. Additionally, 
CBD can antagonise the adverse effects of THC, such as intoxication and sedation, while also 
having its own therapeutic effect.142,154,158 This suggests value in the co-administration of THC 







1.5.3 Δ-9-Tetrahydrocannabinol/Cannabidiol Interaction 
 
Interactions between CBD and THC produce either enhancing, opposing, or neutral 
effects. These variations in effects are due to differences in dosing, ratios of THC to CBD, routes 
of administration, order of dose (CBD administration either before or simultaneously to THC), 
and differences in treatment duration (chronic vs. acute).137,159 Both pharmacokinetic (kinetic) 
and pharmacodynamic (dynamic) mechanisms control the interactions between CBD and 
THC.137 CBD potentiates the effects of THC (via a kinetic mechanism).137,160,161 CBD hinders 
THC metabolism, heightening the effects of THC.159,162 Conversely, simultaneous co-
administration of CBD and THC may result in attenuation of some effects of THC (via a 
dynamic mechanism).137,160,161,163 CBD is a negative allosteric modulator of the CB1 receptor,155 
causing it to reduce the potency and efficacy of THC.164  
 
1.5.4 The Entourage Effect 
 
In addition to the cannabinoids CBD and THC, phytocannabinoids such as 
tetrahydrocannabivarin, cannabigerol, and cannabichromene, are also present in Cannabis,153 as 
are organic compounds known as terpenes.152,153 Terpenes and phytocannabinoids share a 
precursor molecule,153,165 and these terpenes can result in phytocannabinoid-terpene interactions 
and synergism.153 The interaction of these molecules results in the entourage effect, an increase 
in therapeutic efficacy,153 due to an alteration of pharmacokinetic and pharmacodynamic 
properties.  
 
1.5.5 Pharmacodynamics of Phytocannabinoids 
 
The pharmacodynamic properties of Cannabis is based on the effects of the most 
prominent cannabinoids, THC and CBD. These phytocannabinoids are highly promiscuous and 
interact with many receptors beyond CB1 and CB2 (Table 1.3). THC activation of the CB1 
receptor results in inhibition of neurotransmitter release, via the same mechanism as endogenous 
cannabinoids (Figure 1.2). CBD also antagonises CB1 and CB2 agonists,166,167 which explains 
CBD’s ability to attenuate the side effects caused by THC.137,160,161 Additionally, activation of 




inhibitory synapses, including 5HT, glutamate, GABA, D-aspartate, dopamine, acetylcholine and 
noradrenaline, with both short and long-term effects.137 
 
Table 1.3. THC and CBD actions on various receptors 
Receptor THC CBD 
CB1 Weak partial agonist155 Negative allosteric modulator155 
CB2 Weak partial agonist155 Inverse agonist158,166,167  
GPR55/GPR18 Agonist168 Antagonist165 
5HT1A Agonist169 Agonist170 
µ/σ opioid receptors Positive allosteric modulator171 Positive allosteric modulator171 
PPARγ Agonist172,173  Agonist174 
TRPV1 No effect175 Agonist165,174 
D2High Conflicting evidence176 Partial agonist177 
5HT1A: serotonin 1A receptor; CB1: cannabinoid receptor 1; CB2: cannabinoid receptor 2; CBD: cannabidiol; D2High: 
dopamine D2 high receptors; GPR55: G-protein coupled receptor 55; GPR18: G-protein coupled receptor 18; PPARγ: 
peroxisome proliferator-activated receptor gamma; THC: Δ-9-tetrahydrocannabinol; TRPV1: transient receptor potential 
cation channel subfamily V member 1 
 
1.5.6 Pharmacokinetics of Phytocannabinoids 
 
Route of administration is important when determining the effects of CBM. CBM can be 
administered via smoking/vaporization, orally, oromucosally, and less commonly, topically137,178 
and each route has different onsets and duration of action.155 Furthermore, administration of 
cannabinoid products results in large inter-individual differences in peak plasma concentrations 
and peak effects.137 Smoking/vaporization of Cannabis results in high bioavailability of 
cannabinoids, averaging about 30% for both THC179 and CBD.180 Onset of effect is rapid, 
usually within 5-10 minutes, with a dose-related duration between two and four hours.155 
Although absorption by inhalation is rapid, it is highly variable and depends on depth of 
inhalation, puff duration, and breath hold.137 Oral ingestion of cannabinoids induces a slower 
onset of action (60-180 minutes), lower peak blood levels, and longer duration of effects 
compared to smoking (six to eight hours).137,155 With oral administration, first pass metabolism 
results in low bioavailability of both THC and CBD, ranging between 4-20% and 13-19% for 
THC178 and CBD,181 respectively. Oromucosal administration has an onset of effect of 15-45 
minutes with a duration of 6-8 hours.155 Finally, topical administration of cannabinoids poses a 
problem, as cannabinoids are hydrophobic, so transport across the aqueous layer of skin is the 




The cannabinoids undergo delayed distribution after systemic absorption.137,178,182 THC 
and CBD are both lipophilic and are taken up by fatty tissue and highly perfused organs such as 
the brain, heart, and liver.137,174,178 THC and CBD are highly protein bound, to both albumin and 
lipoproteins,178 with an unbound fraction of 1 – 5%.174,178 The blood-brain barrier (BBB) limits 
THC’s ability to access the brain, contributing to a delay in psychoactive effects compared to 
peak plasma concentrations.137,183 The efflux transporter P-glycoprotein (P-gp) mediates THC’s 
movement across the BBB, and limits the accumulation of THC in the brain.184–186 Conversely, 
CBD is not a substrate of P-gp, and therefore its accumulation in the brain is independent of 
these transporters.187 However, CBD inhibits P-gp,188 resulting in higher brain concentrations of 
THC with co-administration of the two cannabinoids.188 
Cannabinoid elimination occurs mainly by hepatic cytochrome P450 (CYP) enzyme-
mediated metabolism. THC is metabolized by CYP2C9/19, and CYP3A4,178 and CBD is 
hydroxylated by CYP3A4 and CYP2C8/9/19.174 Initial metabolites of THC are 11-hydroxy-THC 
(active) and 11-nor-9-carboxy-THC (inactive),137,178 while CBD is hydroxylated to 7-hydroxy-
CBD (active) and 6-hydroxy-CBD.174 Oral administration results in a greater metabolism of 
THC to 11-hydroxy-THC, therefore causing similar plasma concentrations of THC and the 
active hydroxy metabolite.137,178,189 Via inhalation, plasma values of 11-hydroxy-THC appear 
rapidly and peak shortly after THC administration (about 15 minutes after the start of 
smoking).137,178 CBD also inhibits the formation of THC metabolites catalyzed by CYP3A4, with 
minimal effect on CYP2C9,190 subsequently causing a decrease in the formation of 11-hydroxy-
THC.137,191,192   
Excretion of THC metabolites occurs via feces and urine, with 80-90% being excreted as 
the metabolite, 11-nor-9-carboxy-THC.178 THC metabolites from a single dose can be detected in 
plasma for up to 13 days in chronic smokers (terminal elimination half-life of 12.6 
days),137,178,193,194 and low levels of THC metabolites have been detected after more than 5 weeks 
in urine and feces of cannabis users.137,190 This is likely due to the extensive accumulation and 
release of THC from body fat.137,194 The half-life of CBD is 1-2 days,174,195 with CBD 
metabolites excreted mainly in the feces,174 as hydroxylated derivatives of CBD-7-oic acid, or as 




Tolerance to cannabinoids is mainly due to PD rather than PK mechanisms, because of 
changes in CB1 receptor availability.137,198 Two mechanisms by which this occurs are receptor 
desensitization and receptor downregulation (internalization/degradation of receptor).137,199 PK 
tolerance, while not as common as PD tolerance, is a possibility and is mainly due to changes in 
absorption, distribution, and excretion.137,200 In humans, tolerance is seen after a few doses and 
disappears rapidly following cessation, with tolerance developing to mood, intra-ocular pressure, 
psychomotor performance, nausea, and cardiovascular system effects.137,201,202  
Dosing is an obstacle for health-care professionals prescribing CBM, as the association 
between successful dose and disease state is still unknown. Therefore, dosing relies heavily on 
self-titration.137 The approach for CBM dosing is to “start low, go slow, and stay low”,155 as most 
adverse effects of CBM, due to THC, occur early and are seen with high initial doses.155 As 
patients develop tolerance to psychoactive effects of cannabis quickly over a period of days, 
without tolerance to the benefits, they can maintain the same dose for many years.155  
 
1.6 Cannabis-Based Medicine 
 
CBM is currently used and under investigation for the treatment of many different 
disorders including AIDS wasting syndrome, chemotherapy-associated nausea, Parkinson’s 
disease, and epilepsy.203 Cannabinoids may also be immunosuppressive and have therapeutic 
value in chronic inflammatory disorders, such as MS.204   
 
1.6.1 Cannabis Products  
 
 Medicinal Cannabis products available include synthetic and naturally derived 
prescription products, as well as leafy Cannabis. Prescription products include nabiximols 
(oromucosal spray), cannabis extract (oral capsule), dronabinol (oral capsule), and nabilone (oral 
capsule).205–208 In Canada, leafy Cannabis has been legal for medical use since 2001,107 with 
prescription CBM products available since 2005.209,210  
Two naturally derived Cannabis products are available, nabiximols (Sativex), and 
Cannabis extract (Cannador). Nabiximols, a 1:1 THC:CBD oromucosal spray derived from the 




Spain, Poland, Germany, Denmark, the Czech Republic, Sweden, New Zealand, and Canada.213 
It has been approved in Canada since 2005 for the treatment of MS pain,209 and was later 
approved for cancer-related pain (2007) MS spasticity (2010).209,210,214,215 Cannabis extract 
(Cannador), is most commonly a 2:1 THC:CBD oral capsule.208,216 It has be utilised in research 
studies across Europe and is produced by the Institute for Clinical Research (Berlin, 
Germany).208,216 It has undergone testing in clinical trials for stiffness, spasms, and pain in 
multiple sclerosis, and for anorexia/cachexia in cancer subjects.216 Cannador is not available in 
the United States208 or Canada.217 
Dronabinol (Marinol) and nabilone (Cesamet) are two synthetic oral cannabinoid 
products.205,218 Dronabinol has been approved in the United States since 1985 and is used for the 
treatment of nausea/vomiting associated with chemotherapy, and anorexia due to AIDS weight 
loss.208,219 Dronabinol was previously available in Canada, but was voluntarily withdrawn from 
the Canadian market by its manufacturer205 for unspecified reasons.220 Nabilone is approved in 
both Canada and the United States for chemotherapy-associated nausea and vomiting.208,221,222  
In 2018, the FDA approved Epidiolex (cannabidiol) for the treatment of Lennox-Gastaut 
syndrome and Dravet syndrome in children two years and older.223 This was the first marijuana-
derived drug approved by the FDA.223  
As both naturally derived (nabiximols, Cannabis extract) and synthetic (dronabinol, 
nabilone) prescription products are available, it is important to consider that these two types of 
products may behave differently to produce varied pharmacological effects. Synthetic 
cannabinoids have differences in selectivity, potency, and function compared to naturally derived 
cannabinoids. The synthetic cannabinoids demonstrate greater potency than those that are 
naturally-derived.224  
 
1.7 Efficacy of Cannabinoids for MS in Animal Models 
 
Current literature suggests that CBM has therapeutic benefit for MS symptom treatment. 
A main source of concern with CBM use is the possibility of adverse effects, particularly 
psychoactivity. Current human studies indicate that side-effects are generally well-tolerated,225 




questions remain with respect to CBM, including formulation (which cannabinoid(s) to use), 
dose, and route of administration. Animal studies have evaluated the efficacy of various 
cannabinoids on mitigation of MS symptoms and disease progression.   
 
1.7.1 Disease Progression 
 
Studies using synthetic cannabinoids have investigated the efficacy of these compounds 
with respect to disease progression of animal models of MS. Dexanabinol, a synthetic 
cannabinoid, reduces inflammation in the brain and spinal cord of experimental autoimmune 
encephalomyelitis (EAE) animals, thus suppressing disease progression.227 Likewise, mice 
infected with Theiler’s murine encephalomyelitis virus (TMEV) were used to test the efficacy of 
three synthetic cannabinoids, WIN 55, 212-2, ACEA, and JWH-105, on the progression of the 
disease. These cannabinoids may hinder demyelination and inflammatory processes and favour 
myelin repair, therefore improving neurological deficits of the disease, and allowing for 
recovery.228 Histological studies also determined reductions in microglial activation and a 
decreased number of infiltrating T-cells in the spinal cords of the TMEV mice that were treated 
with the cannabinoids.228 Therefore, these studies suggest a therapeutic benefit to using 
cannabinoids in demyelinating diseases.  
The use of phytocannabinoids, THC and CBD, on EAE disease progression in rats 
demonstrated that THC inhibited clinical and histological signs of EAE. Since there was 
significantly less inflammation in histological studies, THC may be effective at EAE suppression 
and prevention.229 As well, CBD administration at the time of viral infection ameliorated motor 
deficits, which was associated with reduced microglial activation and pro-inflammatory cytokine 
production.230 These studies emphasise the anti-inflammatory and immunomodulatory effects of 
both THC and CBD, and show therapeutic potential of CBM for the treatment of MS.  
Additionally, evaluation of cannabinoid receptor involvement in MS animal models 
suggest the importance of the CB1 receptors in disease progression. CB1 receptor knockout mice 
demonstrated poor tolerance to inflammatory and excitotoxic insults, and subsequently went on 




encephalomyelitis (CREAE) induction.231 In this model, CB1 agonists provide significant 




In addition to disease progression, animal models of MS are used to assess cannabinoids’ 
efficacy at treating the symptoms of MS. The most commonly studied symptom is spasticity. 
Much evidence suggests CBM is a useful option. In a CREAE model of MS, the CB receptor 
agonists, R(+)-WIN 55,212, THC, methanandamide and JWH-133, improve both tremor and 
spasticity, while CB1 and CB2 receptor antagonists, SR141716A and SR144528, exacerbated 
tremor and spasticity.222 Such data suggests the endogenous cannabinoids may be tonically 
active.232 The presence of endocannabinoids in a CREAE mouse model of MS, in relation to 
their influence on spasticity, have also been evaluated. Enhanced levels of endocannabinoids, 
including anandamide (AEA) and 2-arachidonoyl glycerol (2-AG), were demonstrated as 
compared with control or non-spastic CREAE mice.232 Additionally, inhibitors of 
endocannabinoid re-uptake and hydrolysis had a positive impact on spasticity similar to the 
cannabinoid receptor angonists.232 This again suggests a tonic control of spasticity by the 
endocannabinoids that could lead to therapies for MS symptoms.  
In a comparative study of the effects of CBM and baclofen on spasticity in CREAE mice, 
THC:CBD (in a 1:1 ratio) demonstrated a dose dependent decrease in spasticity, with high doses 
showing similar reductions to baclofen.233 In addition to exhibiting similar efficacy, CBM has no 
withdrawal period, a distinct advantage to baclofen where withdrawal from this drug needs to be 
done slowly to avoid dramatic side effects.233 Furthermore, Pryce and Baker234 tested the 
involvement of CB1 and CB2 receptors in spasticity and found that spasticity was induced in 
CB1 knock-out mice after EAE induction, and that CB1 receptor agonists control spasticity and 
CB2 receptor agonists have cross-reactivity, accounting for their therapeutic effect. Despite the 
fact that psychoactivity is due to CB1 receptor agonism,234 the CB1 receptor might be the main 







1.7.3 Limitations of Animal Studies 
 
Animal models are necessary for understanding the underlying mechanisms of MS and 
developing possible treatments. However, no animal model is able to fully capture all aspects 
(clinical, radiological, pathological and genetic) of MS due to its complex nature.235 Therefore, 
supplementation of animal studies with human clinical trials is necessary to fully understand the 
range of effects of various pharmacotherapies in humans.  
 
1.7.4 Side Effects and Toxicity 
 
The most common side effects of CBM observed in human clinical trials include 
dizziness, dry mouth, and somnolence.226 However, most human studies report few adverse 
events and usage is generally well tolerated,225 especially if dose titration is used to help 
minimize adverse events.236,237 THC has a wide safety margin, and it is difficult to determine a 
toxic dose given the variation in purities and exposure routes;238 however THC is intoxicating.239 
CBD has a good safety profile, and is associated with few side effects or toxicity.240 Long-term 
effects of CBM are still unknown as research in this area is limited. Thus far, no association 
between Cannabis use and death has been noted,241,242 though smoking Cannabis can lead to 




Potential of CBM to treat MS is seen in the increase of Cannabis use by individuals with 
MS, the preliminary research done in MS animal models, and the approval of CBM by Health 
Canada. A systematic review on the use of CBM in MS will help further evaluate its potential 
role as a therapeutic option in managing the disease and for identifying areas of potential 
research.  
 





How is cannabis-based medicine (CBM) used for the treatment of multiple sclerosis and 




This thesis will describe the use of CBM for the treatment of MS symptoms and disease 
progression and explain the forms of CBM used by the MS population.  
1.11 Objective 
 






CHAPTER 2: METHODS 
 
2.1 Search Strategy 
 
A literature search was completed using MEDLINE (Ovid Medline® Epub Ahead of 
Print, In-Process & Other Non-Indexed Citations, Ovid Medline® Daily and Ovid Medline® 
1946 to Present), International Pharmaceutical Abstracts (International Pharmaceutical 
Abstracts 1970 to February 2018), and Embase (Embase Classic + Embase 1947 to 2018 Week 
41). A preliminary search was completed on August 29, 2017, and re-run on October 11, 2017 
and February 26, 2018 to identify additional articles (Table 2.1). Systematic review articles and 
bibliographies of relevant articles were hand searched for inclusion of potential studies. Grey 
literature was not searched.  
 
2.2 Inclusion and Exclusion Criteria 
 
All articles published in English that were MS-specific and involved human subjects 
were eligible for inclusion. Both randomized controlled trials and observational studies were 
included; however, individual case reports were not. No publication year limit was applied. 
 
2.3 Review Methods and Quality Assessment 
 
All duplicate records were identified electronically by Mendeley and removed. In 
DistillerSR (Evidence Partner, v2) two reviewers (NB and NA) initially screened titles for 
eligibility, and then the full abstracts. Complete copies of the articles deemed potentially relevant 
were obtained and reviewed independently by both reviewers to determine if they should be 
included. Discrepancies were resolved by a third party (CE) not involved in the original review. 
Data were abstracted into a standardized form by both reviewers and included the following 
information: author, year, study location, study cohort size (“n”), study type/design, primary 
endpoint, study cohort characteristics (e.g. age, sex, MS type/severity), type of product used 
(CBD, THC, both), route of administration, dose, dose regime, comparator, study length, primary 
endpoint results, reported adverse effects, number of patients that withdrew from the study (with 




was not specified, the outcome specified in a power calculation was considered the primary 
outcome. If there was no power calculation, then the first outcome reported in the results section 
was considered to be the primary outcome.245 
Quality assessment was also performed independently by both reviewers (NB and NA) 
using a modified Downs and Black checklist (Appendix A).246,247 The maximum score on the 
checklist is 28, with categories of good (20-28), fair (15-19), and poor (≤ 14).247 Any scoring 
discrepancies were resolved by a third party (CE). Given the heterogeneity of the studies, a meta-
analysis was not performed. 
Table 2.1. MeSH terms and key words for each database  
Database Search Terms (26/02/18) 
Embase 
(Embase Classic + 




• Cannabis sp 
• Marinol 
• Hashish  
• Hash Oil 
• Nabilone 
• Epidiolex  
• Cannabis 
• Cannabi* 
• Medical cannabis 








• Nabiximols  
• Demyelinating disease  
• Multiple sclerosis (explode) 
• Disseminated sclerosis 
• Multiple sclerosis  
 
Medline 
(Ovid Medline® Epub 
Ahead of Print, In-
Process & Other Non-
Indexed Citations, Ovid 
Medline ® Daily and 
Ovid Medline ® 1946 to 
Present) 
• THC 
• Cannabis sp 
• Nabilone 
• Epidiolex  






• Medical marijuana  
• Sativex 
• Nabiximols  
• Dronabinol 
• Dronabinol 
• Demyelinating disease  
• Multiple sclerosis (explode) 
• Multiple sclerosis 







1970 to September 2017) 









• Cannabis sp 
• Nabilone 
• Epidiolex 
• Multiple sclerosis 
• Disseminated sclerosis 






CHAPTER 3: RESULTS 
 
3.1 Study Selection 
 
 Initially, 2756 articles were identified, of which 468 were deemed potentially eligible, 
after title and abstract screening. A total of 60 articles were included in the final review (Figure 
3.1). Of these 60 articles, 26 were randomized control trials (RCTs) and 34 were observational 
studies. Of the 26 RCTs, 15 used intention to treat (ITT) analysis.  
Studies were published between 1981 and 2018, with the majority published after 2010 
(Tables 3.2-3.16). The articles were categorized according to the primary outcome: spasticity 
(n=29), pain (n=8), cognitive function (n=6), adverse events/safety (n=6), bladder dysfunction 
(n=4), balance/walking (n=3), tremor (n=1), progression (n=1), and general symptoms (n=2). 
Results were then further categorised by assessment method to allow for comparability. Study 
lengths ranged from one day to over three years. Most included studies were less than six months 





Figure 3.1. Flow diagram of article inclusion248   
 
Potentially relevant publications 
identified from databases: 
Embase: 1647  
Medline: 741 
IPA: 68 
Other sources: 300 
Total: n= 2756 
Duplicate records 
removed (n= 698) 
Abstracts Screened (n=1545) 
Excluded (n= 513) 
Potentially eligible studies  
(n= 468) 
Eligible studies for inclusion  
(n= 86) 
Records excluded (n=382):  
Abstract only: 94 
No article available: 22 
No cannabinoids/not 
cannabinoid specific: 22 
Not MS specific: 12 
Not English: 44 
Review/editorial/ letter: 173  
Case Study: 15 
 
 
Titles Screened (n=2058) 
Excluded (n = 1077) 
Final Articles to include (n=60): 




General Symptoms: 2 
Pain: 8 




Records excluded (n=26): 
MS symptoms not being 
examined: 2 
Study design only reported:1 
Not an MS-specific cohort: 1 
Factors related to effect of 
cannabis on MS patients: 1 
Duplicate study: 1 
Cost of therapy outcomes 
reported: 4 
Driving ability outcomes 
reported: 1 
Forensic aspects reported: 1 
Genetic polymorphisms 
reported: 1 
Immunomodulation reported: 2 
MRI reported outcomes 
reported: 1 
Receptor regulation outcomes 
reported: 1 
Survey/opinion: 9 
Case study: 1 
Post-hoc analysis: 1 
 
Records added (n=2)  
Reference list: 1 
(October 17, 2018) 
Ovid email update: 1 






Most studies evaluated the use of the oromucosal spray nabiximols (Sativex®) (2.7 mg 
THC, 2.5 mg CBD/100 µL spray), a pharmaceutical grade product. Several studies involved 
other CBM formulations and dried Cannabis. The route of administration, dosing schedules, and 
ratio of Δ9-THC:CBD all varied among studies. 
 









Oral Institute for Clinical 
Research, Germany 
Ratio of 2.5 mg THC:1.25 mg CBD, <5% 
other cannabinoids56,249,250 
Ratio of 0.8-1.8 mg CBD:2.5 mg THC70 
Cannabis Extract 
(Cannador) 




Ratio of 2.5 mg THC, 20 to 30% CBD and 
<5% other cannabinoids251 
Ratio of 2.5 mg THC:0.9 mg CBD225 













3.5 mg THC279 
2.5 mg THC50,56,67,249–251,280  
Nabilone  
(Cesamet) 
Oral Not Stated THC 0.5 or 1 mg capsules281 
ECP002A  
 
Oral Echo Pharmaceuticals 
B.V. 
1.5 mg or 5 mg THC282 
Smoked 
 
Inhalation National Institute on 
Drug Abuse (USA) 
4% THC283 
Smoked Inhalation Not Stated 1.54% THC284 
Smoked (Street 
Cannabis) 
Inhalation N/A Varies81,285–287 
Synthetic THC Oral Not Stated 10 mg or 15 mg THC49 
CBD: cannabidiol; N/A: not applicable; THC: Δ9-tetrahydrocannbinol; USA: United States of America 
 
According to the modified Downs and Black assessment tool, 23/60 (38%) articles were 
considered poor quality, 14/60 (23%) fair quality, and 23/60 (38%) good quality. All the articles 
that were rated as good were published 2003 or later. Thirty-two studies clearly identified a 
primary outcome measure in the introduction or methods, and 15 studies were adequately 
powered for their primary endpoint. Common methodological issues included non-randomized 
designed, inadequate blinding, no power calculation, and lack of consideration for confounding 






Spasticity was assessed in 29 articles (Tables 3.2-3.5). Eleven were RCTs and eighteen 
were observational studies. Ten studies were good quality, nine were fair quality, and ten were 
poor quality. Twenty-two of these studies used nabiximols (Sativex), three used oral Cannabis 
extract (Cannador) with varying ratios (2:1 THC:CBD and 3:1 THC:CBD), five used oral THC 
(dronabinol and ECP002A), and one used inhaled CBM. The assessment measures used included 
both objective and subjective spasticity measures. Six good quality studies found CBM 
statistically beneficial for the treatment of spasticity.   
 
3.2.1 Studies Assessed with the Ashworth Scale or Modified Ashworth Scale 
 
Seven studies,225,249,250,269,270,273,283 four RCTs and three observational studies, assessed 
MS-related spasticity with either the Ashworth scale or modified Ashworth scale (MAS) (Table 
3.2). Two of these studies were good quality, and significantly favoured CBMs; a 3-day RCT 
with crossover design utilizing a Cannabis cigarettes (4% THC),283 and a 12-month follow-up 
study using oral Cannabis extract (2:1 THC:CBD) and dronabinol (2.5 mg THC).249 Two good 
quality studies found no statistical benefit from using dronabinol250 or Cannabis extract.225,250 
Adverse events (dizziness, nausea, fatigue) were generally well tolerated and were similar for all 

























RCT 13 weeks 18–64 years; stable disease 
for the previous 6 months; 
Ashworth score of 2 in two 
or more lower limb muscle 
groups; treatment not 
altered in the 30 days before 
the start of treatment. 




history of psychotic or 
major illness, pregnancy, 
use of THC at any time, and 
use of cannabis in the 30 
days before the start of the 
study, foreign travel 
immunisations over the 15 
weeks of the study, taking 




from baseline to 







Maximum dose of 
25 mg daily, 




No evidence of 
effect of 
treatment. Mean 
changes in total 
Ashworth 
scores (baseline 















MS relapse in 
each treatment 


















14 days Clinically stable spasticity 
with at least one joint 
scoring >/= 2 on the 
Ashworth scale. 
No significant neurological 
(other than MS), 
cardiovascular, or infectious 
diseases; clinical disease 
exacerbation or treatment 
with steroids during the two 
months preceding study 
entry; history of alcohol or 
drug abuse; depression, 
history of psychosis; use of 
cannabinoids during the 
Change in the 
Ashworth scale 
of muscle tone 






Maximum dose of 
30 mg THC/day 
Placebo  Placebo period: 
13.1 +/- 6.3 
(baseline) to 
















































Concentration Test < 21). 
Corey-









3 days Spasticity with at least 
moderate increase in tone 
(score ≥ 3 points on the 
modified Ashworth scale at 
the elbow, hip or knee); 
subjects were allowed to 
continue other treatments 
for spasticity, with the 
exception of 
benzodiazepines, if they had 
been taking stable doses for 
three months or longer; 
subjects could continue 
disease -modifying therapy 
if they had been on a stable 
regimen for at least six 
months; no medication 
changes that would affect 
spasticity scores.  
No patients with a history 
of major psychiatric 
disorder (other than 
depression) or substance 
abuse, substantial 
neurologic disease other 
than MS and 
severe/unstable medical 
illnesses, known pulmonary 
disorders, patients who used 
benzodiazepines to control 













4% THC by weight, 
800mg cigarette 
Average of 4 
puffs/cigarette 




on the modified 
Ashworth scale 



































narcotic medications for 
pain, and those pregnant or 
breastfeeding. No Cannabis 
month before screening and 












3 weeks Right-handed secondary-
progressive MS patients 
with normal right hand 
function, EDSS score 
between 3.5 and 6.5; 
clinically stable disease for 
the preceding 30 days; 
spasticity in at least two 
muscle groups (score ≥ 2 on 
the Ashworth scale for each 
muscle group); stable 
antispastic treatment in the 
preceding 4 weeks; no 
disease modifying therapies 
started in the preceding 6 
months; no clinical 
condition precluding safe 
participation; no 
cannabinoid use or 
concomitant therapy with 
antidepressants, 
psychoactive drugs, 
corticosteroids prior to the 
study entry. 













Placebo Mean change 
(post vs. pre) in 
total Ashworth 
scale was -0.664 
















12 months 18–64 years, stable disease 
for the previous 6 months 
(in the opinion of the 
treating physician, rather 
than as measured by EDSS) 
and problematic spasticity 
(Ashworth score of at least 
Mean change in 
Ashworth score 
from baseline 
(start of main 
study) to the 











































































30 days  Age > 18 years, diagnosis 
of MS since at least six 
months, moderate to severe 
spasticity in at least two 
districts of upper and/or 
lower limbs, absence of 
clinical or neuroradiological 
relapses at least six months 
prior to study entry, EDSS 
score >3.5, no history of 
psychosis, no presence of 
pace-maker, aneurysms 
clips, or neurostimulator or 
brain/subdural electrodes. 
All subjects were taking 
antispastics, with baclofen 
being the most common. 
Assessment of 
spasticity using 
the MAS after 





N/A MAS:  
T0: 4+/-0.7  
T30: 3+/-0.9 
p=0.01 















1 month MS for at least 6 months, 18 
years of age, no clinical or 
neuroradiological relapses 
for at least 6 months prior to 
Change in MAS 
score in pain 
and no-pain MS 
patients before 
Nabiximols 
(Sativex) (n=20; 10 
with neuropathic 
pain, 10 without) 





























study entry, an EDSS score 
3.5, right-handedness, right 
side being the most 
affected, no history of 
psychosis, no safety 
contraindication for 
TMS/laser procedures. 
Patients with severe pain 
from other concomitant 





No pain group 
before 
treatment: 4 
























BP: blood pressure; EDSS: expanded disability status scale; MAS: modified Ashworth scale; MS: multiple sclerosis; N/A: not applicable; RCT: randomized controlled trial; THC: Δ9-




3.2.2 Studies Assessed with the Numerical Rating Scale  
 
Thirteen studies assessed MS-spasticity using the numerical rating scale (NRS) (Table 
3.3).254,255,268,274,277,257–259,261,263–266 All thirteen studies utilized nabiximols (Sativex). Three 
studies were RCTs and ten were observational. Three good quality studies found a statistically 
beneficial effect with nabiximols (Sativex) use.254,258,263 One good quality study found no 
statistical benefit with use of nabiximols (Sativex).255 Adverse events (AEs) were generally well 
tolerated with dizziness and fatigue being commonly reported; however, some studies also 












Table 3.3. Spasticity assessment with numerical rating scale 
Reference Study Design Intervention  
Length 











Collin et al. 
2007254b 
RCT 6 weeks >18 years of age, stable 
disease for at least 3 
months before study 
entry; significant 
spasticity in at least two 
muscle groups 
(Ashworth score ≥ 2 or 
more; not getting 
adequate relief using 
current therapy; stable 
treatment for at least 30 
days before entry and 
during the study. 
Effective contraception 
for subjects of 
childbearing potential. 
Use of cannabis or 
cannabinoids prohibited 
during the study and for 
at least 7 days before 
visit 1. No psychosis or 
severe psychiatric 
disorder other than 
depression, known 
alcohol or substance 
abuse, severe 
cardiovascular disorder, 
history of seizures, 
pregnancy/lactation, 
planned travel abroad 
during the study. 
The change 
from baseline 
in the severity 
of spasticity 
based on a 
daily diary 
assessment by 
the subject on 
NRS to the 








of 48 sprays/day 
Mean dose of 
9.4 sprays/day  
Placebo (n= 
65) 
Mean dose of 
14.7 
sprays/day 
Mean change in 
NRS spasticity 
scores for the 
CBM group at 










0.52 points, in 







Collin et al. 
2010255b 
RCT 99 days MS of at least 6-months 
duration, and at least a 
3-month history of 
spasticity due to MS 
(not wholly relieved 
with current therapy). 
Anti-spasticity regimen 





baseline to the 












Mean dose of 
15.4 
sprays/day 
Mean change in 
treatment NRS 
score from 




1.05 points.  
Most common 













Table 3.3. Spasticity assessment with numerical rating scale 
Reference Study Design Intervention  
Length 











days preceding study 
entry. No subjects with 
symptoms of spasticity 
not due to MS, 






Mean dose of 
8.5 sprays/day  
Mean change in 
placebo NRS 
score from 




0.82 points.   
Treatment 
difference: -0.23 
points, in favor 






RCT 16 weeks  MS for at least 6 
months; spasticity 
because of MS for at 
least 3 months (not 
wholly relieved with 
current medication), at 
least 20% reduction in 
NRS score in phase A; 
No new alterations of 
medications from Phase 
A. No concomitant 
disease or disorder that 
had spasticity-like 
symptoms; medical 
history that suggested 
that relapse/remission 
was likely to recur 
during the study, no 
cannabis or cannabinoid 
use 30-days prior to 
study entry, concurrent 
history of significant 
psychiatric, renal, 
hepatic, cardiovascular 
or convulsive disorders, 
Change in 
spasticity 
NRS from the 
point of 
randomization 
to the end of 






of 12 sprays/day 
Mean dose of 
8.3 sprays/day  
Placebo 
(n=117) 





improved in the 
active treatment 
group by 0.04 
units, from a 
baseline score 
of 3.87 points. 
In the placebo 
group, there was 
a mean 
deterioration of 
0.81 from a 
baseline score 




between the two 
groups in mean 
spasticity NRS 
was 0.84 points 
(95% CI: 1.29 







at a rate greater 

















Table 3.3. Spasticity assessment with numerical rating scale 
Reference Study Design Intervention  
Length 











known or suspected 




significant (p = 
0.0002). 
Flachenecker 
et al. 2014259b 
Observational 12 months ≥18 years of age, 
moderate to severe MS 
spasticity (spasticity 
causing limitations 
activities of daily living, 
activities in social 
environment, or where 
there is a risk of 
spasticity-related 
complications), start of 
nabiximols at inclusion, 
patients characteristics 
according to labelling or 
nabiximols, consent, 
completion of initial 
MOVE 2 study. 
No spasticity not due to 
MS, cognitive 





the NRS, after 









mean number of 
sprays was 6.2 
+/- 2.6 (range of 
2-12) 
N/A Mean NRS 
score showed a 
significant 
improvement 
from 6.2 at BL 




























et al. 2014258b 
Observational 3-4months >18 years of age, 
moderate to severe 
MSS, start of 
nabiximols at inclusion 
(start of nabiximols no 
more than 7 days before 
inclusion and 
prescription decision 
independent of study 
participation), patient 
characteristics 







the NRS, after 





Mean dose of 
6.9 sprays/day 
N/A At baseline, 
mean spasticity 
NRS score was 
6.1 points in the 
entire study 
population, and 
after one month 
this value 
improved by 
12.3% to 5.2 
points 
p=0.0001 

















Table 3.3. Spasticity assessment with numerical rating scale 
Reference Study Design Intervention  
Length 











nabiximols, and signed 
consent.  
No spasticity due to 
causes other than MS, 
patients with relevant 
cognitive impairment, 
deficits of German. 
Koehler et al. 
2014261b 
Observational 9 months All patients with MS 




2011 and January 2013 
at the Marianne Strauss 
hospital in Berg, 
Germany 
Change in 
NRS score in 






Mean dose of 4 
sprays/day 





decreased to 3.0 
within the first 






AEs leading to 
discontinuation: 
dizziness, 





Observational 3 months ≥ 18 years of age; 
moderate-to-severe 
spasticity; start Sativex 
at time of enrollment; 
patient signed consent; 
concomitant medication 
and other management 
approaches are stable 
unless change is 
indicated in patients' 
clinical evaluation. No 
non-MS spasticity, 
relevant cognitive 
impairment, or deficits 
of relevant language. 
Improvement 
in NRS scores 
from baseline 




Mean dose of 
6.1 sprays/day 
at visit 1, and 
5.1 sprays/day 
at visit 3 
N/A At BL, mean 




to 5.5 points in 
patients with 













Ferre et al. 
2016257c 
 
Observational 48 weeks Moderate-to-severe 
spasticity due to MS 
(NRS score of ≥4); have 
evidence of no adequate 
Change in 






N/A Mean NRS 
score was stable 
in non-
responders (7.2 











Table 3.3. Spasticity assessment with numerical rating scale 
Reference Study Design Intervention  
Length 











response to traditional 
antispastic medications. 
No subjects use of 
cannabis or 
cannabinoids in the 30-
days prior treatment 









at baseline and 
7.5 at 4 weeks, 





7.6 at baseline 












up period was 
40 +/- 28 
weeks 
MS patients treated with 
Sativex and followed at 
the MS Center of the 
University of Bari. 














NRS score of 
2.5 points, from 
the value of 8.7 
at the baseline 
assessment to a 
value of 6.2 at 
the first month 
follow-up. 
p= 0.0001 














lack of appetite, 
seizures.  
Poor (13) 
Patti 2016266c Observational 6 months Resistant to other 
medications for MS 
spasticity with a score 
of ≥ 4 on the spasticity 
0–10 NRS  
No severe 
cardiovascular disease 
or psychiatric disorders, 
pregnant women, 
individuals known to 
use psychoactive 
Change in 






Mean dose of 
6.8 sprays/day 
N/A 61.9% of the 
population had 
≥ 20% NRS 
improvement 
and remained on 
treatment. 25% 
of the cohort 
had achieved 
clinically 
















Table 3.3. Spasticity assessment with numerical rating scale 
Reference Study Design Intervention  
Length 















Patti et al. 
2016265c 
Observational 6 months >18 years; NRS score 
≥4; not responding to 
common and ongoing 
antispastic drugs (used 




history of psychiatric 
diseases, use of street 
cannabis and/or other 
psychoactive drugs; MS 
spasticity NRS score <4 
 











number of puffs 





between BL and 
4 weeks NRS 
score. At BL, 
the NRS score 
was 7.5, and at 
4 weeks, the 




























Russo et al. 
2016268 
Observational 6 months NRS ≥4; evidence of 
inadequate response to 
the traditional anti-
spastic medications 
(thus, all the patients 
had to be in treatment 
with Sativex); age > 18 
years; a diagnosis of 
definite MS since at 
least six months; right-
handed with normal 
right-hand function; the 








Mean dose of 8-
9 sprays/day 
N/A NRS at BL: 8  
NRS at 1 
















Table 3.3. Spasticity assessment with numerical rating scale 
Reference Study Design Intervention  
Length 












relapses since at least 
six months; EDSS 
ranging from 3.5 to 8; 
no changes in anti-
spastic and immune-
modulator agents before 
their study enrollment; 
no history of psychiatric 
disorders, 
cardiovascular diseases 






Observational 3 months ≥18 years of age, 
moderate-to-severe MS 
spasticity, THC:CBD 
prescribed up to 7 days 
before enrollment and 
independent of study 
participation, consent, 
must be national 
language, other 
medications stable for 
study.  
No spasticity due to 
reason other than MS, 
cognitive impairment. 









Mean dose of 6 
sprays/day 
 
N/A Mean NRS 
score: 6.9 (BL) 
5.4 (3 months) 
p=0.0001 







AE: adverse event; BL: baseline; CBD: cannabidiol; EDSS: expanded disability status scale; GI: gastrointestinal; MS: multiple sclerosis; MSS: multiple sclerosis spasticity; N/A: not 
applicable; NRS: numeric rating scale; RCT: randomized controlled trial; THC: Δ9-tetrahydrocannabinol; UTI: urinary tract infection 
b: study sponsored by pharmaceutical company 




3.2.3 Studies Assessed with the H/M Ratio 
 
Three studies,262,272,282 two RCTs and one observational study, used the ratio between the 
maximum H reflex and maximum M response (H/M ratio),44 as an assessment measure (Table 
3.4). One good quality282 and two fair quality studies262,272 found no significant treatment effect 
with 4 weeks of nabiximols (Sativex) or oral THC use. All three studies were published since 
































4 weeks ≥18 years of age; 
progressive primary or 
secondary MS of at least 12 
months’ duration; relapse-
free for at least 3 months 
prior to screening; EDSS 
score between 3.0 and 6.5; 
MAS score of at least ‘‘1+’’ 
in one limb; stable 
antispasticity medication 2 
months prior to screening. 
No modifications to DMTs 6 
months prior to or during the 
study. No concomitant 
disease that will 
cause/interfere with 
spasticity; botulinum toxin 
injection for spasticity in the 
4 months prior to screening; 
any known or suspected 
history of psychotic illness, 
alcohol or substance abuse; 
epilepsy or hypersensitivity 
to cannabinoids; significant 
cardiac, renal or hepatic 
disease; pregnant or 
lactating, or subjects of 
child-bearing potential 
unless willing to use 
contraception; known 
contraindications to Sativex 
The 
treatment 
effect on the 
H/M ratio 
from 






dose of 12 
sprays/day 























Mean dose of 
10 sprays/day 
Mean H/M Ratio 
Sativex: BL: 0.33, 
week 4: 0.31 
Placebo: BL:0.31; 
week 4: 0.31 
No significant 
difference in the 
change from 
baseline to week 4 
in the H/M ratio 
under treatment 
























only, 5 patients 
to placebo only 
and 15 patients 
































4 weeks  ≥18 years of age, diagnosis 
of progressive (primary or 
secondary) MS (revised 
McDonald criteria), disease 
duration of 41 years, 
clinically stable for at least 
30 days before the start of 
the challenge phase. 
Ashworth score of ≥2 
(range, 0-4) and a Kurtzke 
EDSS score between 4.5 and 
7.5 at baseline (range, 0-10). 
Dosage and treatment 
regimen of spasmolytic 
therapy stable for at least 30 
days before study 
participation and remained 
stable throughout study. 
Current use of Δ9-THC was 
exclusionary, as confirmed 
per urine drug screen. 
Difference 














or 5mg THC) 
Dose levels 
were 3, 5, and 
8 mg (twice 
daily), 
leading to a 
total daily 




H/M ratio change 
from BL in 
placebo group was 
-0.002 and in 
active group was -
0.008; there was 
no significant 
difference 



















Observational 4 weeks ≥18 years of age, diagnosis 
of primary or secondary 
progressive MS least two 
years of disease or diagnosis 
of relapsing-remitting MS 
with a disease duration of at 
least 6 months, no clinical or 
radiological evidence of a 
relapse in the previous 6 
months; presence of 
moderate to severe spastic 
hypertonia; failure of clinical 
response to other anti-
spasticity medications. 
No contraindications to 
treatment with Sativex or to 






and 4 weeks 













within the studied 
population at BL 
and 4 weeks as to 
both H-reflex and 

































Results Adverse Events Quality 
Score 
(/28) 
Medications kept stable 
during the study.  
AE: adverse event; BL: baseline; DMT: disease modifying therapy; EDSS: expanded disability status scale; HC: healthy control; H/M ratio: H-reflex and M-response ratio; MAS: 
modified Ashworth scale; MS: multiple sclerosis; RCT: randomized controlled trial; THC: Δ9-tetrahydrocannabinol; TMS: transcranial magnetic stimulation 





3.2.4 Studies Assessed with other outcome measures 
 
Six studies,45,46,48–51 used assessment measures not previously described (Table 3.5). Two 
studies were RCTs. Of these six measures, only one, the stretch reflex, is validated.47 One 
study,45 evaluating time to treatment failure, was determined to be of good quality, and reported 
significant improvement with nabiximols (Sativex). Adverse effects were generally mild and 








Table 3.5. Spasticity assessment (other outcome measures) 























Clinically definite MS 
and spasticity due to 
MS 26-64 years old, 
history intolerable 
adverse events from 




ratings BL vs 




dose of THC 
between 2.5-
15 mg; 7.5mg 
deemed 
optimum dose 
Placebo The level of 
spasticity reported 
by patients was 













distortions. At 7.5 





Notcutt et al. 
201245b 
RCT 5 weeks MS subjects receiving 
Sativex for spasticity 
at least 12 weeks prior 
to screening, and who 
were judged to have 
been receiving benefit 
from and showing 
tolerability to Sativex. 
Other spasticity 
medications were 
stable for at least 3 
months prior to study 
entry and during the 
study. No 
concomitant disease 
or disorder that 
caused or influenced 
spasticity. No subjects 
unable to rate their 
level of spasticity or 
distinguish it from 
other MS symptoms. 
No subjects that 
received botulinum 
toxin or rimonabant 3 
months prior to study 
entry. No history of 
The time to 










Mean dose of 
9.0 sprays/day 
Median TTF with 
Sativex: >28 days 












spasms (n=4, 2 in 















Table 3.5. Spasticity assessment (other outcome measures) 



















no subjects with 
known or suspected 








Not specified Spasticity, 
presumably of spinal 
















Placebo  The changes in 
spasticity scores 
between the 
groups at 180 
minutes are 
significant (p < 
0.01); summed 




summed scores of 





being "high" after 











with MS and treated 
with THC/CBD from 
the first time the 
treatment was used in 





spasticity in MS 
patients during 
the study period 
(yes or no 
answer based on 
prescribing 
doctor’s 










dose of 5 
sprays/day 
N/A Treatment was 
deemed highly 
effective in 80% 




were presented in 
52% of subjects: 
dizziness (n = 11), 
muscle weakness 
(n = 7), 
somnolence (n = 
6), diarrhea (n = 
3), oral 
discomfort (n = 
2), dry mouth (n = 
2), blurred vision 
(n = 2), agitation 
(n = 1), nausea (n 
= 1), and paranoid 








Table 3.5. Spasticity assessment (other outcome measures) 
















Observational 4 weeks Spasticity with MAS 
< 4 in at least one of 
the following: flexor 
muscles of the wrist, 
flexor muscles of the 
forearm, extensor 
muscles of the leg, 
foot plantiflexors,; no 
significant peripheral 
nervous system, no 
parkinsonism, no 
exposure to oral or 
smoked cannabinoids 
in the 30 days before 
starting study, no 
botulinum toxin 
injections and no 
dosage variation of 
other drugs that 
affects spasticity and 
pain 30 days before 
study, and nabiximols 
approved label 
requirements. No 
limitations related to 
age and degree of 
disability were 



















N/A The mean EMG 
improvement at 4 









Messina et al. 
201748c 
Observational 2 years (730 
days) 
≥18 years of age, 
NRS score ≥4, not 
responding to 
common and ongoing 
antispastic drugs 
(used under their 
approved label). No 
severe cardiovascular 
diseases, past history 
of psychiatric 









Mean dose of 
6.3 sprays/day 
N/A 631 (39.5%) 
subjects 
discontinued 













Table 3.5. Spasticity assessment (other outcome measures) 











Results Adverse Events Quality 
Score 
(/28) 
cannabis and/or other 
psychoactive drugs, 
pregnancy and MS 
spasticity NRS score 
<4. 
AE: adverse event; BL: baseline; CBD: cannabidiol; EMG: electromyography; MAS: modified Ashworth scale; MS: multiple sclerosis; N/A: not applicable; NRS: numeric rating scale; 
RCT: randomized controlled trial; TTF: time to treatment failure; THC: Δ9-tetrahydrocannabinol 
b: study sponsored by pharmaceutical company 






Bladder dysfunction was assessed in four studies (Table 3.6).54–57 Two of these studies 
were good quality RCTs, and two were poor quality observational studies. One good quality 
RCT comparing dronabinol (2.5mg THC), oral Cannabis extract (2:1 THC:CBD), and placebo 
on urinary incontinence, found a significant decrease in daily incontinence episodes for both 
Cannabis extract and THC.56 One good quality study found no significant change in daily 
incontinence episodes with nabiximols (Sativex) use.57 Adverse events were generally well-








Table 3.6. Bladder assessment 
Reference Study Design Intervention  
Length 













RCT 14 weeks Aged 18–64 years with 
clinically definite or 
laboratory-supported 
multiple sclerosis who, 
in the opinion of the 
treating doctor, had had 
stable disease for the 
previous 6 months, with 
Ashworth score of 2 in 
two or more lower limb 
muscle groups. Stabilise 
factors affecting 
spasticity were not 
altered 30 days before 
start of treatment.  
No ischaemic heart 
disease, active sources 
of infection, 
immunisations 
associated with foreign 
travel during the study, 
and medications such 
beta interferon, which 




past history of psychotic 
illness, major illness in 
another body area, 
pregnancy, use of THC 
at any time, and use of 
cannabis in the 30 days 




judged by the 
3-day diary 
entry at BL 









possible dose of 





Change from BL: 











showed a 25% 
improvement, and 









UTIs in all 
three groups; 




Kavia et al. 
201057b 
RCT 69 days MS with symptoms of 
OAB who fail to 
respond adequately to 
first-line therapies, 
stable dose of 








of 8 sprays/3 
Placebo 
(n=68) 


















Table 3.6. Bladder assessment 
Reference Study Design Intervention  
Length 












medication for at least 
14 days prior to study 
entry and during the 
study, and at least three 
incontinence episodes 
over five consecutive 
days during the baseline 
period. No presence of 
urinary tract infection or 





of use of cannabis or 
cannabis-derived 
medicines (street 
cannabis, dronabinol or 
nabilone) within 7 days 
of study entry, 
hypersensitivity to 
cannabinoids, a history 
of major psychiatric 




personality disorder or 
history of substance 
abuse, severe 
cardiovascular disorder, 
history of epilepsy or 
significant renal or 
hepatic impairment, and 
concomitant use of 







hours and 48 
sprays/day 
Mean dose of of 
8.91 sprays/day  
Sativex: mean 
change from BL: -
1.08 
Placebo: mean 








a main AE. 
Maniscalco et 
al. 201854c 
Observational 4 weeks Subjects with MS 
(revised McDonald’s 















Table 3.6. Bladder assessment 
Reference Study Design Intervention  
Length 











criteria) with NRS score 
≥ 4, failure to respond 
adequately to first-line 
antispastic treatments 
and who fulfill the 
requirements for 
THC/CBD oromucosal 
spray as add-on 
medication. Have at 
least 6 points at 
OABSS, refractory to 
conventional 
anticholinergic therapy 
carried out for at least 3 
months.  





presence of LUTDs due 
to other conditions, 
history of use of herbal 
cannabis in 7 days prior 
to study entry, use of 
anticholinergic or 
alpha-blocker drugs for 
urinary symptoms, 
history of diabetes, 
cerebrovascular disease, 
or neurological disease 
other than MS, severe 
cardiovascular disorder 









of 12 sprays/day 
Mean dose of 
3.8 sprays/day 
BL: 17 
4 weeks: 12  
p=0.001 
experienced 
mild dizziness  




16 weeks  
(8 weeks of 
2.5 mg THC 
and CBD per 
18-65 with advanced 











N/A No significant 
improvement 
from baseline 












Table 3.6. Bladder assessment 
Reference Study Design Intervention  
Length 











spray and 8 
weeks of 2.5 
mg THC only) 
conventional treatment. 
Detrusor overactivity 
proven on cystometry 
and a Mini-Mental State 
Examination 12 score > 
27. Patients using street 
cannabis were required 
to stop four weeks prior 
to and during the study 
and urine tests for 
cannabis were carried 
out prior to recruitment. 
No detrusor failure, an 
indwelling catheter or 
inability to fulfil the 




8 weeks of 
treatment 
Maximum dose 
of 48 sprays/day 





















AE: adverse event; BL: baseline; CBD: cannabidiol; CE: Cannabis extract; CNS: central nervous system; LUTD: lower urinary tract dysfunctions; LUTS: lower urinary tract symptoms; 
MS: multiple sclerosis; N/A: not applicable; NRS: numeric rating scale; OAB: overactive bladder; OABSS: overactive bladder symptom score; RCT: randomized controlled trial; THC: 
Δ9-tetrahydrocannabinol; UIE: urinary incontinence episode; UTI: urinary tract infection 
b: study sponsored by pharmaceutical company 








Pain was assessed in eight studies,67,70,226,237,253,275,280,281 and included one article 
evaluating muscle stiffness.70 Six studies were RCTs and two were observational studies. Six 
studies were good quality, one was fair quality, and one was poor quality. Four studies used 
nabiximols, two used dronabinol (2.5mg THC), one used nabilone (0.5mg or 1mg THC) in 
conjunction with gabapentin, and one used Cannabis extract (0.8-1.8 mg CBD:2.5 mg THC). 
Four good quality studies found CBM to have a beneficial effect on MS-related pain.   
 
3.4.1 Studies Assessed with the Visual Analogue Scale 
 
The Visual Analogue Scale (VAS) as an assessment for pain was evaluated in two 
studies,253,281 one RCT and one observational study (Table 3.7). VAS pain scores showed a 
significant decrease with the use of nabilone and gabapentin combined, compared to placebo, in 
one good quality RCT.281 Dizziness was a common adverse event in both studies.  
 
3.4.2 Studies Assessed with the Numerical Rating Scale 
 
The Numerical Rating Scale (NRS) was used to assess CBM for pain in five studies 
(Table 3.8).67,226,237,275,280 There was a significant reduction in NRS score with dronabinol 
treatment in one good quality RCT.67 Additionally, nabiximols (Sativex) use resulted in a 
decrease in NRS score in one good quality RCT226 and in a fair quality observational trial.275 
Two good quality studies, one utilizing nabiximols (Sativex)237 and one utilizing dronabinol,280 
found no significant decrease in NRS score. Dizziness, dry mouth, nausea, and tiredness were 
common adverse events.  
 
3.4.3 Studies Assessed with the Category Rating Scale  
 
The category rating scale (CRS) was used to evaluate muscle stiffness before and after 
Cannabis extract (Cannador) treatment in one good quality study (Table 3.9).70 Cannabis extract 
was more effective than placebo at providing relief after 12 weeks of treatment. Common 







Table 3.7. Pain assessment with visual analogue scale 
Reference Study Design Intervention  
Length 














RCT 9 weeks MS-induced NPP, RRMS 
(defined by 2005 McDonald 
criteria) and a score of 4 as 
per DN4 criteria.  Age 18–65 
years old; EDSS score of 
<6.5, VAS pain score for 
NPP symptoms 50, with pain 
symptoms present for at least 
3 months; and current NPP 
treatment with GBP that is 
not effective at a stabilized 
dose of 1,800 mg daily for at 
least 1 month. No pregnancy 
or breastfeeding, history of 
alcohol or substance abuse, 
past or current 
nonpsychotic/psychotic 
emotional disorders, 
significant renal or hepatic 
insufficiency, cardiovascular 
disease (i.e., heart failure, 
cardiac arrhythmias) or 
uncontrolled hypertension, 
hypersensitivity to nabilone 
or its derivatives, and current 
reported use of CBs and/or 
related products; subjects 
with other possible 
confounding causes of 











0.5 or 1 mg 
capsules of 
nabilone; final 
dose of 1 mg 






in VAS pain 
intensity was 
greater, on 







during both the 
titration and 
maintenance 















Observational 6 weeks Subjects with CNP (a 
constant or intermittent 
sensory symptom with 
unpleasant feelings or pain, 
lasting for more than 1 month 
and having a stereotyped 
neurological distribution and 
superficial localization) 


















mean VAS for 
pain. The 
mean VAS 















Table 3.7. Pain assessment with visual analogue scale 
Reference Study Design Intervention  
Length 














medications and therapies 
were maintained during the 
study. No psychosis, 
substance abuse, 
cardiovascular disorders, and 
pregnancy. 
particularly 
low after 3 
weeks of 
treatment.  
AE: adverse event; CB: cannabinoid; CNP: central neuropathic pain; DN4: Douleur Neuropathique 4; EDSS: expanded disability status scale; GBP: gabapentin; HIV: human 
immunodeficiency viruses; MS: multiple sclerosis; N/A: not applicable; NPP: neuropathic pain; RCT: randomized controlled trial; RRMS: relapsing remitting multiple sclerosis; VAS: 
visual analogue scale 







Table 3.8. Pain assessment with numerical rating scale 
Reference Study Design Intervention  
Length 
















cross over trial 
3 weeks Age 18-55 years, and central 
pain at the maximal pain site 
with a pain NRS score >3. 
Central pain is pain in a 
body territory with abnormal 
sensation to pinprick, touch, 
warmth, or cold, evaluated 
by the bedside or with 
quantitative sensory testing, 
corresponding to at least one 
lesion in the central nervous 
system. Concurrent spasm 
related pain or other pain 
was allowed if the patient 
was able to distinguish it 
from central pain.  
No subjects who had used 
marihuana within the last 
three months. Subjects were 
not allowed to use 





(NRS score) in 






of 10 mg 
THC/day 



































Rog et al. 
2005226c 
RCT 4 weeks Subjects with MS for at least 
6 months, central pain of at 
least 3 months’ duration for 
which a nociceptive cause 
appeared unlikely and 
expected to remain 
otherwise stable during the 
study. A stable neuropathic 
pain medication regimen 
was maintained during the 2 
weeks immediately before 
screening and throughout the 
study. Changes in 
medications or procedures 
expected to affect central 
MS pain were prohibited. No 
subjects with chronic 













Mean dose of 
9.6 sprays/day  
Placebo 
(n=32) 




6.58, week 4: 
3.85 
Placebo: BL: 











subjects on CBM 
developed at 












Table 3.8. Pain assessment with numerical rating scale 
Reference Study Design Intervention  
Length 







Results Adverse Events Quality 
Score (/28) 
spasticity-associated aching 
pain, secondary entrapment 
syndromes, or acute MS-
related pain. Patients were 
excluded if their sensations 
were not subjectively 
deemed painful or if they 
had spasticity or painless 
spasms alone or another 
noncentral pain mechanism 
was considered more likely. 
Patients taking TCAs were 
required to take a maximum 
dose of 75 mg/day. No 
Cannabinoid/Cannabis use 
at least 7 days before 
screening or during the study 
was permitted. No history of 
major psychiatric disorder 
(other than depression 
associated with their 
underlying condition), 
severe concomitant illness, 
seizures, history or suspicion 
of substance abuse, 
concomitant severe 
nonneuropathic pain or the 
presence of illness such as 
diabetes mellitus, or 
scheduled procedures 
requiring general anesthesia 
during the study. Patients 
were also excluded if they 
were pregnant, lactating, 




RCT 98 days CNP due to MS, for at least 
3 months with a sum score 
of at least 24 on a pain 0–10 
point NRS on the last 6 days 











Mean dose of 
11.1 
sprays/day 
The number of 
responders at 
the 30 % 
improvement 
level in mean 
AEs with severe 
intensity were 
observed most 









Table 3.8. Pain assessment with numerical rating scale 
Reference Study Design Intervention  
Length 







Results Adverse Events Quality 
Score (/28) 
Analgesic regimen stable for 
at least 2 weeks preceding 
the study entry day. Subjects 
were required to have had an 
average of three or more 
sprays of THC/CBD per day 
in the 7 days prior to 
completion of phase A, 
shown tolerability to the 
study medication, and 
maintained a stable 
treatment regimen 
throughout the study for all 
neuropathic pain 
medications. No severe pain 
from other concomitant 
conditions, pain that was not 
of a central neuropathic 
origin that would interfere 
with the patient’s assessment 
of neuropathic pain due to 
MS, patients with a history 
of significant psychiatric 
(other than depression 
associated with their 
underlying condition), renal, 
hepatic, cardiovascular, or 
convulsive disorders, or with 
a sensitivity to cannabis or 
cannabinoids, participants 
who had experienced an 
adverse event in phase A 
were also excluded from 
phase B. 
treatment, 
defined as an 
improvement 





baseline to the 






Mean dose of 
8.8 sprays/day  
pain NRS 
score in the 
last week of 
treatment 




45% in the 







system disorders.  
75% in treatment 
group and 62% 

















Aged 18–70 years, stable 
disease symptoms and 
moderate to severe CNP 
(NRS ≥4) at maximal pain 
area for at least 3 months as 

















was 1.92 and 
Double-blind 
and open-label 
period 92.9% of 
patients 
experienced at 








Table 3.8. Pain assessment with numerical rating scale 
Reference Study Design Intervention  
Length 







Results Adverse Events Quality 
Score (/28) 
No peripheral pain 
syndromes, pre-existing 
psychotic disorders, severe 
cardiac diseases, or known 
substance abuse. Continuing 
therapy with amitriptyline 
and gabapentin, if started at 
least 3 months ago with a 
stable dose and oral intake of 
tramadol as rescue 
medication for acute pain 
attacks, was allowed.  














Turri et al. 
2018275 
Observational 1 month MS according to Polman 
criteria, presence of chronic 
pain, spasticity recalcitrant 
to other drugs, age 18-65.  
No modification of ongoing 
therapy within the past 3 
months; relapses in the 6 
months prior to and during 
the study; high-dosage 
steroids in the last 6 months; 
pregnancy; severe 
kidney/liver disease; and 
history of drug abuse or 
mental disorder. 
NRS score for 
pain before 






Mean dose of 
6.9 sprays/day 
N/A A significant 
improvement 
in NRS score 
after drug 
therapy (6.61 
at BL to 3.55 







AE: adverse event; BL: baseline; CBD: cannabidiol; CBM: cannabis-based medicine; CNP: central neuropathic pain; CNS: central nervous system; MS: multiple sclerosis; N/A: not 
applicable; NRS: numeric rating scale; RCT: randomized controlled trial; TCA: tricyclic antidepressant; THC: Δ9-tetrahydrocannabinol 
b: study sponsored by pharmaceutical company 

























RCT 12 weeks Ages 18-64 years, stable 
disease for the previous 6 
months and troublesome 
and current score of at 
least 4 on an 11 point 
CRS. All physiotherapy 
regimens or medications 
likely to affect spasticity 
were not altered in the 30 
days before study start. 
No active sources of 
infection or 
immunomodulatory 
drugs that might affect 
spasticity, fixed tendon 
contractures, severe 
cognitive impairment, 
history of psychosis, 
major illness, pregnancy 
and cannabis use in the 















of 25 mg/day 
At the end of the 
study, 24.5% 











at week 12, 
(defined as 
categories 0-3 
on the CRS) 
was 29.4% in 
the CE group 











AE: adverse event; CE: Cannabis extract; CRS: category rating scale; MS: multiple sclerosis; RCT: randomized controlled trial; UTI: urinary tract infection 







Cognition was assessed in six studies58,81,276,285–287 (Tables 3.10 and 3.11). Two RCTs, 
evaluating nabiximols (Sativex); and four observational studies, evaluating dried Cannabis. 
Three studies were poor quality, one was fair quality, and two were good quality. The 
observational studies provided little, if any, information regarding intervention length or adverse 
events; since dry Cannabis was used, dosing and formulation were not reported. 
 
3.5.1 Studies Assessed with other cognition outcome measures 
 
The effect of dry Cannabis on Diagnostic and Statistical Manual of mental disorders 
(DSM-IV) diagnosis in MS patients81 and on the 10/36 spatial recall test60 was assessed in poor 
quality observational studies (Table 3.10). Adverse events were not reported in either study. 
 
3.5.2 Studies assessed with the Paced Auditory Serial Addition Test (PASAT) 
 
Four studies 58,276,285,286 evaluated CBM use and the Paced Auditory Serial Addition Test 
(PASAT) (Table 3.11). Two good quality RCTs utilizing nabiximols (Sativex)58,276 found no 
significant change in PASAT score between treatment and placebo groups. Adverse events were 








Table 3.10. Cognition assessment (other) 


























used cannabis at 
least once in 
their lives. Ten 
subjects (7.7%) 
were defined as 
current cannabis 
users based on 




with MS attending 
an outpatient MS 
clinic in Toronto, 
Ontario, Canada, 














Time of last 
Cannabis use 











Cannabis users and 
controls on any 
individual DSM-IV 
diagnostic category. 
The proportion of 
patients meeting 
DSM-IV criteria for 
a psychiatric 
diagnosis was 
higher in cannabis 







Pavisian et al. 
2015287c 
Observational Cannabis group 
were daily users 
Right-handed 
individuals, age 18-
60 years, normal or 
corrected-to-normal 
vision. No history of 
brain injury, illicit 





steroids in the past 3 
months, 
neuropsychological 











instructed not to 
smoke 24 hours 








were more impaired 










DSM-IV: diagnostic and statistical manual of mental disorders; MS: multiple sclerosis 







Table 3.11. Cognition assessment with paced auditory serial addition test 






















3 weeks 18 and 60 years of 
age, right-handed with 
normal right-hand 
function; a baseline 
EDSS 18 score 
ranging from 3.5 to 
6.5; a stable disease 
for at least 30 days 
before study entry and 
no systemic 
corticosteroid therapy 
within 4 weeks of 
randomization; 
significant spasticity 




agents stable, before 
the study entry, for at 
least 1 and 6 months, 
respectively; no 
history of epilepsy of 
alcohol or substance 
abuse and no major 
medical illnesses; no 
psychiatric disorders 
or cognitive 
impairment at first 





drugs; no female 
patient who was 
pregnant, lactating, or 
planning pregnancy 
during the course of 
the study; and no 
Change in 







Mean dose of 
8.2 sprays/day 
Placebo  




change found in 
PASAT score in 
placebo (mean 




















Table 3.11. Cognition assessment with paced auditory serial addition test 



















RCT 48 weeks MS of any subtype, at 
least moderate levels 
of MS spasticity not 
wholly relieved with 
current anti-spasticity 
therapy; be on a stable 
medication regimen 
(i.e., not changed in 
the last three months 






willing to abstain 
from alternative 
cannabinoid use for 
30 days prior to 
screening and 
throughout the study.  
No current or past 
history of drug or 
alcohol abuse or 
significant psychiatric 





pregnant, lactating or 
planning pregnancy; 
had received an 
investigational 
medicinal product 
within 12 weeks of 
































subjects in the 
Sativex group 
and 32.2% of 
subjects in the 
placebo group 
experienced 
AEs. The most 










least one SAE, 
while there 
were no SAEs 
reported in the 









Table 3.11. Cognition assessment with paced auditory serial addition test 















or abnormalities that 
could either put the 
patient at risk, affect 
the patient’s ability to 
participate or 
influence the result of 
the study. 
Honarmand 
et al. 2011285c 
Observational Average age 
























Subjects (18-65) who 
used cannabis 
recently and whose 
urine tested positive 
for cannabinoids only 
(no other illicit drugs) 




cannabis use less than 
12 hours prior to 
testing were excluded.  
No history of 
traumatic brain injury, 
psychotic illness, 
concurrent neurologic 
diseases, and poor 
visual acuity (less 
than 20/70 corrected, 
both eyes). No 
subjects who had 
undergone 
neuropsychological 




subjects with MS; 
urine that tested 
negative for 
cannabinoids and 




























lower on the 
PASAT 3.0 
















Table 3.11. Cognition assessment with paced auditory serial addition test 















other illicit drugs. A 
remote history of 
occasional teenage 








times a week 
(n=1) 
 
18-60 years of age.  
No history of brain 
injury, illicit drug use 




with steroids in the 
past 3 months, 
neuropsychological 
testing in the past 
year, claustrophobia, 
mental handicap, and 
psychosis. All 






cannabis and whose 
urine tested positive 
for cannabis 
metabolites only were 
enrolled.  
Control sample: 
Subjects with MS 
who had never used 
cannabis were group-
matched to the 
cannabis group on 
demographic and 
disease-related 








Daily (n=17), 4 
to 5 times a 
week (n=2), 
and 2 to 3 times 








more poorly on 
the PASAT 
















Table 3.11. Cognition assessment with paced auditory serial addition test 















subjects had negative 
urine and saliva tests. 
AE: adverse event; EDSS: expanded disability status scale; MS: multiple sclerosis; PASAT: paced auditory serial addition test; RCT: randomized controlled trial; SAE: serious adverse 
event 
b: study sponsored by pharmaceutical company 




3.6 Balance and Walking 
 
Three studies evaluated the use of CBM for balance/walking (Table 3.12).77,252,284 
Interventions included nabiximols (Sativex) and smoked 1.54% THC Cannabis cigarettes. All 
studies were poor quality and indicated that CBM use results in impaired balance but faster 
walking speed. A comprehensive list of adverse events was not provided in any of the three 
studies; one study reported reasons for discontinuation of nabiximols to be drowsiness and 







Table 3.12. Balance and walking assessment 
Reference Study Design Intervention  
Length 













et al. 1994284 
RCT 1 day 
marijuana 
cigarette 
1 day placebo 
MS by clinical and 
laboratory criteria with 
the predominant clinical 
deficit a spastic 
myelopathy; stiff-
legged gait with 
circumduction of at 
least one leg. 
No cardiac, 
rheumatologic, or 



















Noise Variance:  
Patients: 
Pre smoking EO: 1.02 
Pre smoking EC: 4.83 
Placebo EO: 0.72 
Placebo EC: 3.27 
Cannabis EO: 1.67 
Cannabis EC: 5.37 
Normal Controls: 
Presmoking EO: 0.59 
Presmoking EC: 1.93 
Placebo EO: 0.59 
Placebo EC: 3.20 
Cannabis EO: 0.79 




control, with EO and 
EC, in patients and 
normal controls, as 






Coghe et al. 
201577c 
Observational 1 month Ability to walk for at 
least 6 m regardless of 
the use of aids and the 
ability to take 
nabiximols according to 
medical judgment and 
the Italian Drugs 
Agency criteria. All 
patients were non-










Mean dose of 
5.6 sprays/day 
N/A The patients exhibited 
improved speed (BL 
= 0.43, 1 month = 
0.49; m/sec) 
p<0.001 
Not reported  Poor (13) 
Castelli et 
al. 2019252c 
Observational 12 months ≥18 years; NRS score ≥ 
4, lack of response to 









N/A There was impaired 













Table 3.12. Balance and walking assessment 
Reference Study Design Intervention  
Length 












negative pregnancy test; 
absence of concomitant 
severe cardiovascular 
illnesses; no prior or 
current psychiatric 
diseases; no current use 
of street cannabis and/ 









with continued CBM 
use 
p=0.044 
BL: baseline; EC: eyes closed; EO: eyes open; MS: multiple sclerosis; N/A: not applicable; NRS: numerical rating scale; RCT: randomized controlled trial; THC: Δ9-tetrahydrocannabinol 








One RCT study62 of good quality evaluated the use of Cannabis extract (2:1 THC:CBD) 
for MS-related tremor (Table 3.13). No statistical difference was observed between the Cannador 
and placebo groups. Adverse events included drowsiness and light-headedness and were mild 




Six studies236,251,260,267,271,278 had a primary outcome involving general adverse events 
(AEs) and/or safety (Table 3.14). Three studies were fair quality and three were poor quality, and 
all but one was observational. Five studies utilized nabiximols (Sativex), and one utilized 
dronabinol (2.5mg THC) and oral Cannabis extract (4:1 THC:CBD). Adverse events were mild 








Table 3.13. Tremor assessment with tremor index 






















2 weeks Diagnosis of 
definite MS 
(Poser criteria); 
18-64 years of 







psychotic illness.  
Reduction in 






Maximum dose of 
0.125 mg/kg THC 
twice daily (n=14) 
Mean dose of 
0.107mg/kg twice 





twice a day 
The effect of 
treatment size 
was 0.45 and 





AEs were mild; 
10 patients 
reported AEs 


























Table 3.14. Safety assessment 
Reference 
 






















4 weeks PPMS or SPMS, 
disease duration 1 year, 
mean Ashworth 
spasticity score of 2 or 
more in at least one 
limb during screening, 
EDSS score between 4 
and 7.5. No other 
disease of clinical 




treatment or use of 
cannabinoids in the 2 
months preceding study 
















THC by the end 
of the study 









(p= 0.01), but 





Most AEs were 
rated as mild.  
Fair (17) 











and 225 for 
patients who 
stopped  
MS of any type, with at 




problems, tremor or 
pain that was not 
obviously 
musculoskeletal with 
severity recorded as 
>/=50 mm on a 100-
mm VAS.  
No current or past 
history of drug or 
alcohol abuse, 
significant psychiatric 
illness other than 
depression associated 










Maximum dose of 
48 sprays/day 
Mean dose of 11 
sprays/day 
 
N/A 137 patients 





















Table 3.14. Safety assessment 
Reference 
 















renal or hepatic 
impairment or a history 
of epilepsy.  








Adult patients with 
CNP syndromes 
associated with MS, as 
defined by the Poser 
criteria. No history of 
major psychiatric 
disorder other than 
depression associated 
with their underlying 
condition; severe 
concomitant illness, 
seizures, history or 
suspicion of substance 
abuse; concomitant 
severe on neuropathic 
pain or the presence of 
illness such as diabetes 
mellitus; or scheduled 
procedures requiring 
general anesthesia 
during the study. No 
subjects who were 
pregnant, lactating, 
taking levodopa 
therapy within 7 days 
of study entry or had 









Maximum dose of 
48 sprays/day 
At 1 year of 
treatment: Mean 
dose of 7.5 
sprays/day. In last 
six full days of 
treatment: Mean 
dose of 6.1 
sprays/day  




AEs were rated 
as mild (75%), 
moderate 
(78%), or 
severe (51%).  
AEs that led to 
17 patients 
withdrawing 




































Table 3.14. Safety assessment 
Reference 
 



























Observational At least 4 
weeks 
Subjects with MS using 
marijuana oromucosal 
spray as part of a UK 







Maximum dose of 
48 sprays/day 
N/A 8 subjects 






4 subjects had 
oral mucosal 
white lesions in 




or decreased by 














was 334 days 
(1 to 801 
days) 
≥18 years of age, 
haematology and blood 
biochemistry that was 
considered normal or 
clinically acceptable. 




convulsive or any other 
major disorder, 














Maximum dose of 
8 sprays/3 hours 
and 48 sprays/day 
Mean dose of 10 
sprays/day  
N/A The incidence 
of all-causality 
AEs in this 
study was 95%. 




The most common 
all causality AEs 
were in the 
















Table 3.14. Safety assessment 
Reference 
 















to the study medication 
or taking regular 
levodopa within 7 days 
of study entry; history 
of substance abuse; 
females of child-
bearing potential or 
their partners (unless 
willing to ensure 
effective 
contraception); 
pregnant or lactating 
females or those 
planning pregnancy; 
subjects with any 
physical abnormality at 
screening; subjects 
intending to donate 
blood during the study; 










Observational 12 months ≥ 18 years with 
moderate or severe 
MS-related spasticity 
who had not responded 
adequately to other 
antispasticity 
medications and who 
were prescribed 
Sativex spray 
independently of a 
patient’s potential 
participation in the 
study.  
At the treating 
physician’s discretion, 








Mean dose of 6.6 
sprays/day 
N/A 57 adverse 
events of mild 
(72%), 
moderate (16%) 
or severe (12%) 
intensity were 
reported by 41 
patients (20% 


















Table 3.14. Safety assessment 
Reference 
 











Results Adverse Events Quality 
Score 
(/28) 
excluded, or those with 
a medical or 
psychological disorder 
that would limit their 
ability to understand 
questions and complete 
the questionnaires. 
AE: adverse event; CNP: central neuropathic pain; CNS: central nervous system; EDSS: expanded disability status scale; GI: gastrointestinal; MS: multiple sclerosis; N/A: not applicable; 
PPMS: primary progressive MS; SAE: serious adverse event; SPMS: secondary progressive MS; THC: Δ9-tetrahydrocannabinol; VAS: visual analogue scale 




3.9 General Symptoms 
 
Two studies,82,256 one RCT of good quality and one observational study of poor quality, 
had no specific symptom measure, and therefore assessed general symptom management of 
nabiximols (Sativex) (Table 3.15). There was no significant difference between placebo and 
nabiximols (Sativex) for treating the primary symptom score (PSS) in a good quality RCT.82 The 








Table 3.15. General symptom assessment 















RCT 6 weeks Stable over the 
preceding four weeks 
(no relapse), 
medication not 
changed in the last 
four weeks; be willing 
to abstain from 
alternative 
cannabinoid use for 
seven days prior to 
screening and 
throughout the study; 
volunteer one of the 
five target symptoms 
at a sufficient level of 
severity (spasticity, 
spasms, bladder 
problems, tremor or 
pain that was not 
obviously 
musculoskeletal). No 
current or past history 
of drug or alcohol 
abuse; significant 
psychiatric illness 
other than depression 
associated with MS; 
serious cardiovascular 
disorder; significant 
renal or hepatic 
impairment or history 
of epilepsy; planned 
visit abroad during the 
active study. Caution 
was exercised for 
patients taking drugs 
metabolized by 
certain cytochrome 
P450 enzymes (TCAs 
and anticonvulsants). 










of 120 mg THC 
and 120 mg 
CBD per day 
with no more 
than 20 mg of 
each in 3 hours  
































Table 3.15. General symptom assessment 











Results Adverse Events Quality Score 
(/28) 
Etges et al. 
2016256b 
Observational Duration of 
exposure ranged 
from 1 to 4283 
days (mean of 954 
days) 
Patients prescribed 












of 12 sprays/day 
Mean dose of 
5.4 sprays/day 































AE: adverse event; CBD: cannabidiol; DCP: data collection period; GI: gastrointestinal; MS: multiple sclerosis; N/A: not applicable; PSS: primary symptom score; RCT: randomized 
controlled trial; TCA: tricyclic antidepressant; THC: Δ9-tetrahydrocannabinol; UK: United Kingdom; VAS: visual analogue scale 









The effect of dronabinol (Marinol) on MS disease progression was assessed in one RCT 
of good quality (Table 3.16)279 using the expanded disability status scale (EDSS) score as a 
measure of progression. No statistically significant difference in EDSS score progression was 
seen between treatment and placebo groups. Adverse events (AEs) were similar between placebo 
and treatment groups in both quantity and quality. Common AEs included dizziness, fatigue, and 































RCT 36 months  18–65 years; PPMS or SPMS, 
evidence of disease 
progression in the preceding; 
an EDSS score of 4·0–6·5 at 
baseline; no cannabis use for 
the duration of the trial. 
No use of 
immunomodulatory/disease 
modifying therapies 12 
months prior; systemic 
corticosteroid use in the 
previous 3 months; 
predominant relapsing-
remitting disease in the 
previous 12 months; MS 
relapse in the previous 6 
months that was likely to 
have affected patients’ EDSS 
scores; history of previous 
psychosis or other serious 
medical illness; pregnancy; 
serious cognitive impairment; 
cannabinoid use within the 
previous 4 weeks. 
 
Time to EDSS score 
progression of at 
least 1 point from a 
baseline EDSS 
score of 4.0, 4.5, or 
5.0 or at least 0.5 
points from a 
baseline EDSS 
score of 5.5 or 
greater (confirmed 
by a physician at the 





Maximum dose of 
28 mg (8 
capsules), 
depending on 

















35% patients on 
dronabinol had at 
least one serious AE 
compared with 28% 
of patients on 
placebo (most 
common being 
admission to hospital 
for MS-related 
issues). The median 
number of AEs were 
11/person in the 
dronabinol group, 
and 10/person in the 






















AE: adverse event; EDSS: expanded disability status scale; MS: multiple sclerosis; PPMS: primary progressive multiple sclerosis; RCT: randomized controlled trial; SPMS: secondary 






CHAPTER 4: DISCUSSION 
 
Multiple sclerosis is a disease where the use of alternative therapies is common. 
Cannabis and Cannabis-based medicine (CBM) have been available for treating some MS 
symptoms for several years. However, a better understanding of the potential role of CBM in MS 
is still needed.  
A systematic search of the literature yielded 2756 articles, with 60 included in the final 
review. Most studies (n=37) evaluated the use of CBM for the treatment of MS spasticity and/or 
pain; other studied symptoms included cognition, bladder dysfunction, balance/walking, tremor, 
and an evaluation of safety/adverse events. The majority of included studies were observational 
in design and published since 2010. A variety of CBM products were evaluated, although 
nabiximols was the most commonly studied intervention. In general, the literature confirmed that 
CBM may benefit MS pain and spasticity, while highlighting the need for more, better quality 
research for other MS symptoms. Reported adverse effects were mild; however, more long-term 
studies are needed to accurately examine the potential adverse effects of CBM in MS, 
particularly as it relates to cognition.  
Due to the high variability between studies, interpreting and comparing results of the 
current literature is a challenge. Substantial heterogeneity was due to variations in study 
populations, products and doses studied, length of interventions, outcome measures, and study 
quality. The most obvious variation between study populations was related to prior Cannabis use 
and MS phenotype. Prior Cannabis use was not consistent between study cohorts and was not 
always reported. Some studies required subjects to have no Cannabis use anywhere from 7 days 
to three months prior to the study start, while others required Cannabis-naïve subjects. Few 
studies implemented urine testing251 to evaluate cannabinoid use prior study start, or to ensure 
the placebo/comparator group was abstaining from cannabinoid use.249,279 While past Cannabis 
use does not impact dose of nabiximols administered or incidence of adverse events,288 it may 
impact long-term adverse events, such as cognition289–291 and treatment effect.  
The MS phenotype also varied between cohorts. Many studies indicated the need for 
participants to have a progressive form of the disease (either secondary progressive or primary 




should include subjects with relapsing-remitting MS. The majority of current disease-modifying 
therapies are only indicated in relapsing disease because of their anti-inflammatory properties.92 
Since cannabinoids are immunomodulatory154,157 it would seem feasible that they may also 
benefit individuals with relapsing MS.  
Both synthetic and naturally derived cannabinoid products were evaluated, although 
nabiximols (Sativex) was the most commonly used therapy (n=40). Nabiximols is a prescription 
product with 2.7 mg THC: 2.5 mg CBD per spray. It is available in over 20 countries with an 
indication for MS spasticity and pain,208,212 and many MS clinicians are familiar with its use.  
There is value in administering THC and CBD together, because THC is used to reduce 
MS pain and spasticity,142,143 whereas CBD counteracts the negative intoxicating effects of 
THC.142,154,158 Nabiximols is also a naturally-derived product, which may be seen advantageous, 
as natural products are often presumed to have fewer and less serious adverse events.224 
However, it is still unknown which type of product, synthetic or natural derived, is best in a 
clinical setting.   
The oromucosal administration of nabiximols allows THC and CBD to avoid first-pass 
metabolism before entering the systemic circulation.292 This avoids the formation of the active 
metabolite 11-hydroxy-THC137,178 which is present with oral administration.137,178,189 Presence of 
11-hydroxy-THC results in a more rapid onset of intense psychoactive effects compared to THC 
or Cannabis.178,293,294 While smoking also avoids first-pass metabolism,178 it can lead to 
respiratory issues243,244 and is therefore not a desirable method of administration. 
Nabiximols is self-titrated due to individual variations in tolerability. Maximum allowed 
doses in the included studies were inconsistent and ranged from 12 sprays/day (32 mg and 30 mg 
of THC and CBD, respectively) to 48 sprays/day (130 mg and 120 mg of THC and CBD, 
respectively). It is interesting to note that these higher doses are above the recommended 
maximum of 12 sprays/day.295 Given that the mean number of sprays reported in the included 
studies was 6-7 in a 24-hour period, it is assumed that a dose of 48 sprays/day was rarely reached 
due to adverse effects. Self-titrated doses of the placebo comparator were consistently higher (up 
to 19.1 sprays/day226) than the active product.45,57,255,262,276,58,62,67,70,82,226,237,254 Therefore, the 
maximum allowable dose for nabiximols may have been so high to allow for the increase self-




Other prescription products evaluated included oral synthetic cannabinoids (dronabinol, 
nabilone), and oral Cannabis extract formulations (Cannador). The maximum doses of oral 
synthetic THC products ranged from 2 mg/day281 (nabilone, administered with gabapentin) to 28 
mg/day279 (dronabinol); Cannabis extract (Cannador) had a maximum daily dose of 30 mg/day 
THC.225  
Street Cannabis was also evaluated in four studies, one of which indicated that most 
subjects that had consumed Cannabis for years, including prior to MS diagnosis.285 The other 
three did not specify length of Cannabis use, however in all studies Cannabis was used at least 
biweekly. While those with MS may use street Cannabis to treat their symptoms, it is difficult to 
standardize key factors such as dose (ratio of CBD:THC, and other cannabinoids present in the 
Cannabis), smoking technique (breath hold, depth of inhale, etc.), and the duration of use.  
Intervention length ranged from one day to three years, with most studies having a 
duration of exposure between one and three months. Beneficial effects of CBM, especially for 
spasticity, occur within the first four weeks of treatment.255,258,265,296 If there is no effect in that 
time, the subject is unlikely to find relief with CBM.255 Additionally, self-titrating doses typically 
plateau at around four weeks of treatment.82 A trial of at least one month, then, would allow 
adequate time for a subject and his/her clinician to assess symptom response to CBM treatment. 
Longer durations of exposure are needed to evaluate adverse effects, such as memory or 
cognitive impairment, and to evaluate CBM on disease progression. Of the six studies assessing 
adverse effects/safety, four were at least 12 months long, and therefore more likely to identify 
long-term adverse events with regular CBM use. However, the RCTs evaluating cognitive 
function were only three weeks and four months in duration, arguably too short to accurately 
determine the impact of CBM on cognitive function longer term.  
A variety of subjective and objective assessment measures were used by the studies 
included in this review. A Multiple Sclerosis Task Force associated with the Academy of 
Neurologic Physical Therapy reviewed 63 measures of MS symptoms. Ten measures were 
deemed “highly recommended” due to their psychometric properties, clinical utility, or both.40,41 
While these recommendations do not include any measures specifically for spasticity or pain, 
two self-reported questionnaires that assess overall well-being, the Multiple Sclerosis Quality of 




related to pain and/or spasticity.40,78,79,297 Two of the most prominent assessment measures used 
by the included studies for pain and/or spasticity were the Ashworth/Modified Ashworth Scale 
(MAS) and the Numerical Rating Scale (NRS). The NRS, while not a highly recommended 
measure, is still considered valid and reliable for spasticity assessment, more so than the 
Ashworth scale.43 The Ashworth and modified Ashworth scales were used as the primary 
assessment measure for spasticity in 7 studies, and are the most widely used measures in clinical 
practice.283 These scales are objective; however, there is risk of inter-rater differences. If raters 
are not trained or trained differently, then reliability is decreased298 which makes comparison of 
results from different studies challenging. Additionally, the Ashworth Scale may not be suitable 
for clinical trials of anti-spasticity agents because it is poorly related to simultaneous muscle 
reflex activity.276,299 Three studies used the H/M ratio, the ratio between the maximum H reflex 
and maximum M response,44 to assess spasticity. The H-reflex is a monosynaptic reflex and it 
activated by stimulating afferent nerve fibres.44,300 It is similar to muscle stretch reflex, and is 
increased with spasticity.44,300 A limitation of this measure is that it can be influenced by 
technical and patient factors. For example, the M response, the maximum response of a muscle 
when the motor nerve is directly stimulated, may be influenced by a number of factors (how 
relaxed the arm is, how warm the subject is, and the positioning of the probe).44  
The Paced Auditory Serial Addition Test (PASAT) is a highly recommended measure for 
cognition, and it is included in the Multiple Sclerosis Functional Composite (MSFC).40,59 Most 
cognitive function studies utilized the PASAT as their primary assessment measure. This test has 
good psychometric properties of internal consistency and test-re-test reliability and is highly 
sensitive.301 However, interpretation of the PASAT must be done critically because this 
assessment is negatively affected by age, IQ, and math ability.301 It is also susceptible to practice 
effects, therefore an improved or higher score may be due to either a practice effect or a 
treatment effect.301  
Study quality was most often affected by lack of blinding, lack of a power calculation, 
non-randomized trial design, and industry sponsorship of studies. Blinding is a prominent 
challenge in cannabinoid trials, even with a matched placebo. Many subjects, especially prior 
Cannabis users,288,302,303 notice the psychoactive adverse events (AEs) associated with 




the blinding technique used. Of these twenty-seven, nineteen also indicated blinding of the 
assessor(s). However, despite blinding, recognizable adverse effects may have resulted in 
unblinding.254 Four studies assessed the effectiveness of subject blinding, two assessed blinding 
of subjects as well as treating physicians (physicians responsible for monitoring dose, adverse 
effects and general medical care and safety) and three assessed blinding of those performing the 
assessment measures. In most cases, subjects and treating physicians were able to correctly 
identify if the subject was on active treatment or placebo.62,67,250,251 However, assessors were not 
able to correctly identify the treatment group and there was no association between the assessor’s 
opinion and the treatment used.62,250,251 Therefore, it is less likely that objective measures would 
be impacted by unblinding or the placebo effect.283  
Several studies (n=41) did not report a power calculation, and some of the trials that did 
were underpowered. The lack of a power calculation and inadequate sample size can lead to false 
negative results that are ultimately inconclusive.304   
No included articles compared CBM to currently used treatments for MS symptoms or 
progression. Active comparators allow for a more realistic assessment of the potential for CMB 
in MS. As well, since many of the current medications used to treat MS symptoms often result in 
adverse effects similar to CBM (e.g. dizziness, drowsiness, and nausea),100,305 there is less risk of 
bias from unblinding and/or the placebo effect.281,282   
Both observational and RCTs were included in the review, although non-randomized 
studies were inherently of lower quality. However, observational studies, unlike RCTs, provide 
real-world results,306 are often of longer duration than RCTs, and have increased generalizability. 
Because of this, observational studies are especially useful for assessing long-term effects of 
CBM.  
While the sponsorship of studies does not affect the quality score or discount positive 
outcomes, it is important to note when interpreting results. In this review, industry sponsored 
studies often had higher quality scores, most likely due to adequate resources to ensure study 
quality, and increased experience in conducting interventional research. Twenty-three studies 
were sponsored by pharmaceutical companies, assessing spasticity (n=12), bladder dysfunction 
(n=1), cognition (n=1), pain (n=3), safety (n=4), and general symptoms (n=2); the majority were 




Comparable to past systematic reviews,98,99,296,307,308 CBM use resulted in frequent but 
mild adverse events (AEs) that were well-tolerated. Common AEs were fatigue, dizziness, 
nausea, and dry mouth. A concerning AE with CBM use is cognitive dysfunction. Cannabis use 
is associated with cognitive dysfunction, and interferes with brain development,289–291 especially 
verbal memory.309 Since cognition is negatively affected in MS,310,311 there is increased risk of 
cognitive decline with cannabinoid use in the MS population.312 However any observed 
cognitive dysfunction in those with MS using Cannabis cannot be solely attributed to Cannabis, 
as cognitive dysfunction is a symptom of the disease.310,311 Additionally, delirium can occur in 
MS,313 and this could also be potentiated or exacerbated with cannabinoids use.314–316  
 
4.1 Limitations of the Current Study 
 
 Although the current systematic review presents a comprehensive overview of studies 
using a cannabinoid product for the treatment of any MS symptom, limitations exist. First, only 
English studies were included. Forty-four non-English articles were excluded and therefore their 
results were not considered in this review. Authors were not contacted for further information, 
and assessments and data extracted were based solely on information reported in the study.245 
Additionally, as with all systematic reviews, there is a risk of publication bias.245 However, given 
that many of our studies reported null or negative findings, publication bias does not appear to be 
a concern in our case. Limitations also exist with the quality assessment tool. A modified Downs 
and Black checklist was used, with quality levels defined as good (≥20/28), fair (15-19/28) and 
poor (≤ 14/28).247 However, lower quality scores have also been deemed acceptable in other 
reviews.245,317 Related, the quality assessment itself is subjective, and challenging when studies 
have poor reporting.245 The use of two independent reviewers, as well as a third reviewer to 
resolve any discrepancies helped to alleviate this issue.245 Finally, the heterogeneity of studies 







4.2 Future Directions 
 
Future research on the role of CBM in MS should include high-quality, long-term studies 
evaluating adverse events, with a specific focus on cognitive dysfunction. Since individuals with 
MS are already at risk for cognitive decline, the use of CBM may worsen this,312 and more 
research in this area is needed. More research is also needed on the potential for cannabinoids to 
treat MS disease progression, given the immunomodulatory and anti-inflammatory properties of 
cannabinoids, and in particular CBD.154,157 Therefore, future research should also aim to increase 
clinical knowledge of other cannabinoid products/formulations, for example Cannabis oil and 
other CBD-prominent products.  
While long-term side effects of cannabinoids in the MS population needs further 
research, current reported side effects of CBM (dizziness, nausea) are common to those seen 
with regularly used MS symptom medications.98–100 Additionally, MS medications like baclofen 
must be taken for weeks before a full effect is seen,100 while the effects of nabiximols are 
observed fifteen to forty-five minutes after administration.155 Nabiximols can also be stopped 
suddenly without risk, unlike other MS medications,99,100 as there are no direct withdrawal 
symptoms.58 Finally, while cognitive dysfunction is a concern with cannabinoid use, common 
MS treatments (baclofen, tizanidine) may also affect cognition, although evidence is 
limited.283,318 Therefore, when assessing the use of CBM in the MS population, it is important to 
assess both the positive and negative aspects of the treatment, and compare this to medications 
commonly used to treat MS and its associated symptoms. Finally, future work should evaluate 
the combination of cannabinoids with other MS medications, including the disease-modifying 




 This systematic review concludes that cannabinoids may present a modest and variable 
reduction in subjective spasticity and pain in those living with MS. Future studies must be high-
quality and long-term to provide robust evidence of the potential of CBM in MS, particularly for 
symptoms of bladder dysfunction, tremor, and balance/walking. Also, due to their 




treatment of MS disease progression.154,157 Cannabinoids appear to be safe in MS, as adverse 
events were generally mild and well-tolerated. However, more long-term studies are needed in 
order to assess the effect of cannabinoids on cognition in individuals with MS. Ultimately, more 
work needs to be done with respect to CBD products and MS, specifically its potential use in 
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Appendix A: Modified Downs and Black Quality Assessment Tool 
 
Table A.1. Modified Downs and Black checklist 247 
Item Criteria Score 
Reporting 
1 Is the hypothesis/aim/objective of the study clearly described? Yes = 1 
No = 0 
2 Are the main outcomes to be measured clearly described in the 
Introduction or Methods section? 
If the main outcomes are first mentioned in the Results section, 
the question should be answered no. 
Yes = 1 
No = 0 
3 Are the characteristics of the patients included in the study 
clearly described? 
In cohort studies and trials, inclusion and/or exclusion criteria 
should be given. In case-control studies, a case-definition and 
the source for controls should be given. 
Yes = 1 
No = 0 
4 Are the interventions of interest clearly described? 
Treatments and placebo (where relevant) that are to be 
compared should be clearly described. 
Yes = 1 
No = 0 
5 Are the distributions of principal confounders in each group of 
subjects to be compared clearly described? 
A list of principal confounders is provided. 
Yes = 1 
No = 0 
6 Are the main findings of the study clearly described? 
Simple outcome data (including denominators and numerators) 
should be reported for all major findings so that the reader can 
check the major analyses and conclusions. (This question does 
not cover statistical tests which are considered below). 
Yes = 1 
No = 0 
7 Does the study provide estimates of the random variability in 
the data for the main outcomes? 
 In non-normally distributed data the inter-quartile range of 
results should be reported. In normally distributed data the 
standard error, standard deviation or confidence intervals 
should be reported. If the distribution of the data is not 
described, it must be assumed that the estimates used were 
appropriate and the question should be answered yes. 
Yes = 1 
No = 0 
8 Have all important adverse events that may be a consequence 
of the intervention been reported? 
This should be answered yes if the study demonstrates that 
there was a comprehensive attempt to measure adverse events. 
(A list of possible adverse events is provided). 
Yes = 1 
No = 0 
9 Have the characteristics of patients lost to follow-up been 
described? 
Yes = 1 




Table A.1. Modified Downs and Black checklist 247 
Item Criteria Score 
This should be answered yes where there were no losses to 
follow-up or where losses to follow-up were so small that 
findings would be unaffected by their inclusion. This should be 
answered no where a study does not report the number of 
patients lost to follow-up. 
10 Have actual probability values been reported (e.g. 0.035 rather 
than <0.05) for the main outcomes except where the probability 
value is less than 0.001? 
Yes = 1 
No = 0 
External Validity  
11 Were the subjects asked to participate in the study 
representative of the entire population from which they were 
recruited? 
The study must identify the source population for patients and 
describe how the patients were selected. Patients would be 
representative if they comprised the entire source population, 
an unselected sample of consecutive patients, or a random 
sample. Random sampling is only feasible where a list of all 
members of the relevant population exists. Where a study does 
not report the proportion of the source population from which 
the patients are derived, the question should be answered as 
unable to determine. 
Yes = 1 
No = 0 
Unable to Determine = 0 
12 Were those subjects who were prepared to participate 
representative of the entire population from which they were 
recruited? 
The proportion of those asked who agreed should be stated. 
Validation that the sample was representative would include 
demonstrating that the distribution of the main confounding 
factors was the same in the study sample and the source 
population. 
Yes = 1 
No = 0 
Unable to Determine = 0 
13 Were the staff, places, and facilities where the patients were 
treated, representative of the treatment the majority of patients 
receive? 
For the question to be answered yes the study should 
demonstrate that the intervention was representative of that in 
use in the source population. The question should be answered 
no if, for example, the intervention was undertaken in a 
specialist centre unrepresentative of the hospitals most of the 
source population would attend. 
Yes = 1 
No = 0 
Unable to Determine = 0 
Internal Validity - Bias 
14 Was an attempt made to blind study subjects to the intervention 
they have received? 
Yes = 1 
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Item Criteria Score 
For studies where the patients would have no way of knowing 
which intervention they received, this should be answered yes. 
Unable to Determine = 0 
15 Was an attempt made to blind those measuring the main 
outcomes of the intervention? 
Yes = 1 
No = 0 
Unable to Determine = 0 
16 If any of the results of the study were based on “data 
dredging”, was this made clear? 
Any analyses that had not been planned at the outset of the 
study should be clearly indicated. If no retrospective unplanned 
subgroup analyses were reported, then answer yes. 
Yes = 1 
No = 0 
Unable to Determine = 0 
17 In trials and cohort studies, do the analyses adjust for different 
lengths of follow-up of patients, or in case-control studies, is 
the time period between the intervention and outcome the same 
for cases and controls? 
Where follow-up was the same for all study patients the answer 
should yes. If different lengths of follow-up were adjusted for 
by, 
for example, survival analysis the answer should be yes. 
Studies where differences in follow-up are ignored should be 
answered no. 
Yes = 1 
No = 0 
Unable to Determine = 0 
18 Were the statistical tests used to assess the main outcomes 
appropriate? 
The statistical techniques used must be appropriate to the data. 
For example nonparametric methods should be used for small 
sample sizes. Where little statistical analysis has been 
undertaken but where there is no evidence of bias, the question 
should be answered yes. If the distribution of the data (normal 
or not) is not described it must be assumed that the estimates 
used were appropriate and the question should be answered yes. 
Yes = 1 
No = 0 
Unable to Determine = 0 
19 Was compliance with the intervention/s reliable? 
Where there was non-compliance with the allocated treatment 
or where there was contamination of one group, the question 
should be answered no. For studies where the effect of any 
misclassification was likely to bias any association to the null, 
the question should be answered yes. 
Yes = 1 
No = 0 
Unable to Determine = 0 
20 Were the main outcome measures used accurate (valid and 
reliable)? 
For studies where the outcome measures are clearly described, 
the question should be answered yes. For studies which refer to 
other work or that demonstrates the outcome measures are 
accurate, the question should be answered as yes. 
Yes = 1 
No = 0 
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Item Criteria Score 
Internal Validity – Confounding (Selection Bias)  
21 Were the patients in different intervention groups (trials and 
cohort studies) or were the cases and controls (case-control 
studies) recruited from the same population? 
For example, patients for all comparison groups should be 
selected from the same hospital. The question should be 
answered unable to determine for cohort and case-control 
studies where there is no information concerning the source of 
patients included in the study. 
Yes = 1 
No = 0 
Unable to Determine = 0 
22 Were study subjects in different intervention groups (trials and 
cohort studies) or were the cases and controls (case-control 
studies) recruited over the same period of time? 
For a study which does not specify the time period over which 
patients were recruited, the question should be answered as 
unable to determine. 
Yes = 1 
No = 0 
Unable to Determine = 0 
23 Were study subjects randomised to intervention groups? 
Studies which state that subjects were randomised should be 
answered yes except where method of randomisation would not 
ensure random allocation. For example, alternate allocation 
would score no because it is predictable. 
Yes = 1 
No = 0 
Unable to Determine = 0 
24 Was the randomised intervention assignment concealed from 
both patients and health care staff until recruitment was 
complete and irrevocable? 
All non-randomised studies should be answered no. If 
assignment was concealed from patients but not from staff, it 
should be answered no. 
Yes = 1 
No = 0 
Unable to Determine = 0 
25 Was there adequate adjustment for confounding in the analyses 
from which the main findings were drawn? 
This question should be answered no for trials if: the main 
conclusions of the study were based on analyses of treatment 
rather than intention to treat; the distribution of known 
confounders in the different treatment groups was not 
described; or the distribution of known confounders differed 
between the treatment groups but was not taken into account in 
the analyses. In nonrandomised studies if the effect of the main 
confounders was not investigated or confounding was 
demonstrated but no adjustment was made in the final analyses 
the question should be answered as no. 
Yes = 1 
No = 0 
Unable to Determine = 0 
26 Were losses of patients to follow-up taken into account? 
If the numbers of patients lost to follow-up are not reported, the 
question should be answered as unable to determine. If the 
Yes = 1 
No = 0 
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Item Criteria Score 
proportion lost to follow-up was too small to affect the main 
findings, the question should be answered yes. 
Power 
27* Did the study have sufficient power to detect a clinically 
important effect where the probability value for a difference 
being due to chance is less than 5%? 
Sample sizes have been calculated to detect a difference of x% 
and y%. 
Yes = 1 
No = 0 
Unable to Determine = 0 
*altered from Downs and Black checklist 
 
 
 
